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Summary 
MicroRNAs (miRNAs) represent a highly conserved family of endogenous non-
protein-coding short RNA molecules which perform essential tasks in the regulation of 
eukaryotic cell homeostasis. During the past few years miRNAs have emerged as very potent 
controllers of both innate and adaptive immunity. Despite the profound consequences of this 
discovery for our understanding of immune response regulation hitherto virtually nothing is 
known about miRNA function during innate immunity to Mycobacterium tuberculosis, the 
causative agent of tuberculosis (TB).  
 
Herein a miRNA expression profile of human THP1 macrophages infected with 
pathogenic Mycobacterium tuberculosis H37Rv or the vaccine strain Mycobacterium bovis 
BCG was generated. This led to the identification of miRNA-27a, 133b, 137, 145, 146a, 155, 
339, 340 and let-7e as being differentially regulated during infection. These miRNAs were 
tested for their ability to regulate programmed cell death by using a well established and 
characterized experimental ex-vivo model of death receptor (DR)-induced apoptosis. Of all 
miRNAs tested, only miRNA-133b rendered apoptosis-resistant cells sensitive to tumor 
necrosis factor-alpha (TNFα)-activated cytotoxicity. Moreover, miRNA-133b treatment also 
resulted in exacerbated pro-apoptotic responses to TNF-related apoptosis-inducing ligand 
(TRAIL) or an activating antibody to CD95 (Fas/APO1). Comprehensive analysis, including 
microarray, pulsed stable isotope labeling by amino acids in cell culture (pSILAC) and in-
vitro validation experiments, led to the discovery of the anti-apoptotic proteins Fas apoptosis 
inhibitory molecule (FAIM) and glutathione-S-transferase pi (GSTP1) as direct miRNA-133b 
targets. Moreover, underlining the pleiotropic and synergistic nature of miRNA activity, the 
expression of osteoprotegerin (OPG), a TRAIL decoy receptor, and fatty acid synthase 
(FASN), both genes with important anti-apoptotic and oncogenic features, could be further 
proven as miRNA-133b dependent. The results presented in this work represent the first 
known example of a single miRNA with the ability to influence all three major DR signaling 
pathways. Hence, miRNA-133b represents a very versatile pro-apoptotic molecule that 
achieves its goal by impairing direct regulators of DR ligand sensitivity (FAIM and OPG) as 
well as detoxifying (GSTP1) and survival metabolite-delivering enzymes (FASN). Since the 
expression of the strong pro-apoptotic miRNA-133b has been reported to be decreased in a 
wide array of different cancer types, this apoptosis and cell fate regulator seems to play a 
critical role in the cascade of events leading to cellular transformation and tumor generation. 
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Therefore, given the advantages provided by sequence-specific inhibition, miRNA-133b 
should be explored as a novel therapeutic target for anti-cancer treatment.  
 
 Expression of miRNA-133b in THP1 macrophages and HeLa cells was increased 
following innate immune activation by members of the Toll-like receptor (TLR) family. The 
strongest induction of miRNA-133b synthesis was observed after ligation of TLR3 with 
poly(I:C), suggesting that this miRNA is involved in the anti-viral response. MiRNA-133b 
enhanced the activity of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB). This translated into increased levels of the pro-inflammatory 
interleukins 6 and 8 (IL6/8). Both the elevated activity of NF-κB and production of IL6 and 8 
could be inhibited by co-transfection of miRNA-146a, a well known anti-inflammatory 
miRNA. These results identify miRNA-133b as one further member of a growing list of 
miRNAs with immunomodulatory functions. However, miRNA-133b differs from all other 
miRNAs described so far because it enhances inflammation, rather than dampening it. Since, 
exaggerated inflammation is a major cause of disease and tissue destruction, miRNA-133b 
represents a candidate target for molecular therapeutic intervention.  
 
 This work represents the first detailed characterization of miRNA-133b in the context 
of DR-mediated apoptosis and innate immunity. The molecular interactions dissected herein 
improve the understanding of the regulatory processes associated with tumorigenesis and  the 
immune response. 
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Zusammenfassung 
MicroRNAs (miRNAs) sind eine hoch konservierte Familie endogenener nicht-
protein-kodierender kurzer RNA-Moleküle, die zentrale Aufgaben bei der Regulation der 
eukaryotischen Zellhomöostase erfüllen. MiRNAs wurden in den letzten Jahren als potente 
Regulatoren der angeborenen und adaptiven Immunität beschrieben. Trotz dieser 
Erkenntnisse blieb die Rolle dieser kurzen RNA Moleküle in Infektionen mit Mycobacterium 
tuberculosis, dem Erreger der Tuberkulose, bis dato weitgehend unerforscht.  
 
Im Rahmen dieser Arbeit wurde ein miRNA-Expressionsprofil von menschlichen 
THP1 Makrophagen generiert, die mit dem pathogenen Mycobacterium tuberculosis H37Rv 
oder dem Impfstamm Mycobacterium bovis BCG infizierten waren. Dies ermöglichte die 
Identifizierung von miRNA-27a, 133b, 137, 145, 146a, 155, 339, 340 und let-7e als 
differenziell regulierte miRNAs bei der Infektion. Diese wurden anhand eines gut etablierten 
und charakterisierten ex-vivo-Modells von Todesrezeptor-induzierter Apoptose auf ihre 
Fähigkeit untersucht, das kontrollierte Zelltodprogramm zu beeinflussen. Von allen geprüften 
miRNAs führte nur miRNA-133b dazu, dass Zellen, die unter gewöhnlichen Umständen 
apoptoseresistent sein sollten, nun empfindlich gegen Tumornekrosefaktor-α (TNFα) 
induzierte Zytotoxizität wurden. Darüber hinaus verursachte die Behandlung der Zellen mit 
miRNA-133b auch verstärkte pro-apoptotische Antworten auf TNF-related apoptosis-
inducing ligand (TRAIL) oder einen aktivierenden Antikörper gegen CD95 (Fas/APO1). Eine 
umfassende Studie bestehend aus RNA-Expressionsanalyse, dem sogenannten pulsed stable 
isotope labeling by amino acids in cell culture (pSILAC)- und In-vitro-
Validierungsexperimenten führte zur Identifizierung der anti-apoptotischen Proteine Fas 
apoptosis inhibitory molecule (FAIM) und glutathione-S-transferase pi (GSTP1) als direkte 
Zielgene für miRNA-133b. Desweiteren zeigte sich die Expression von Osteoprotegerin 
(OPG), einem TRAIL- Köder-Rezeptor, und Fettsäuresynthase (FASN), zwei Gene mit 
wichtigen anti-apoptotischen und tumorerzeugenden Funktionen, als miRNA-133b abhängig. 
Dies unterstrich die pleiotrope und synergistische Art der pro-apoptotischen Aktivität dieser 
miRNA. Diese Ergebnisse bilden das erste bekannte Beispiel einer einzelnen miRNA mit der 
Fähigkeit, die drei wichtigsten Todesrezpetorsignalwege zu beeinflussen. Somit stellt 
miRNA-133b ein sehr vielseitiges pro-apoptotisches Molekül dar, das seine Wirkung durch 
die gezielte Beeinträchtigung von Apoptose-Empfindlichkeitsregulatoren (FAIM und OPG) 
sowie entgiftenden (GSTP1) und Metabolit-bereitstellenden Enzymen (FASN) erreicht. Die 
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Stummschaltung der pro-apoptotischen Wirkung von miRNA-133b scheint eine wichtige 
Rolle bei der Tumorentstehung zu spielen, weil die Expression der miRNA in einer Vielzahl 
unterschiedlicher Krebsarten herunterreguliert wird. Aus diesem Grunde könnte die gezielte 
Aktivierung von miRNA-133b oder eine ektopische Expressionssteigerung einen 
interessanten neuartigen Therapieansatz in der Krebsbekämpfung darstellen. 
 
Die Expression von miRNA-133b wurde in THP1 Makrophagen und HeLa-Zellen 
durch Mitglieder der Toll-like Rezeptor (TLR)-Familie aktiviert. Die stärkste Induktion von 
miRNA-133b wurde nach Stimulation von TLR3 mit Poly(I:C) erreicht. Dies deutet 
daraufhin, dass diese miRNA an der anti-viralen Immunantwort beteiligt ist. MiRNA-133b 
Transfektion führte zu einer verstärkten Aktivierung des Transkriptionsfaktors nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB). Dies resultierte in erhöhten Mengen 
an pro-inflammatorischen Interleukinen 6 und 8 (IL6/8). Sowohl die erhöhte NF-κB-Aktivität 
als auch die stärkere Produktion von IL6/8 konnte durch Co-Transfektion von miRNA-146a, 
einer entzündungshemmenden miRNA, blockiert werden. Diese Ergebnisse identifizieren 
miRNA-133b als ein weiteres Mitglied einer wachsenden Anzahl von miRNAs mit 
immunmodulatorischen Funktionen. MiRNA-133b unterscheidet sich allerdings von den 
anderen miRNAs darin, dass sie den Entzündungsprozess fördert anstatt ihn zu dämpfen. Da 
unkontrollierte Entzündungen eine der Hauptursachen von Krankheit und Gewebezerstörung 
sind, bietet sich miRNA-133b als eine interessante potenzielle Angriffsstelle für molekulare 
therapeutische Intervention an. 
 
Diese Arbeit stellt die erste detaillierte Charakterisierung von miRNA-133b im 
Zusammenhang der Todesrezeptor-vermittelten Apoptose und der angeborenen Immunität 
dar. Die erforschten molekularen Wechselwirkungen ergänzen und bereichern das 
Verständnis über die regulatorischen molekularen Mechanismen, die mit der 
Tumorentstehung und Entzündung verbunden sind.  
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Abreviations 
ΔΨm mitochondrial transmembrane potential 
% (v/v) volume percent per volume 
% (w/v) mass percent per volume 
µ micro (10-6) 
bp base pair 
BSA bovine serum albumine 
ctrl. control 
DcR decoy receptor 
DD death domain 
ddH2O double distilled water 
DISC death inducing signaling complex 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DR death receptor 
DTT dithiothreitol 
EDTA ethylendiamintetraacetic acid 
ELISA enzyme linked immunosorbent assay 
EtBr ethidium bromide 
FACS fluorescent-activated cell scanner 
FAIM Fas apoptosis inhibitory molecule 
FasL Fas ligand 
FASN fatty acid synthase 
FCS fetal calf serum 
FLICA fluorescent-labeled inhibitors of caspases 
fw forward 
GSTP glutathione S-transferase pi 1 
h human 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP horseradish peroxidase 
hrs. hours 
IFN interferon 
kDa kilodalton 
kb kilobases 
LPS lipopolysaccharide 
mfe mean free energy 
min. minute 
miRNA microRNA 
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ml mililiter 
MMP mitochondrial membrane permeabilization 
MOI multiplicity of infection 
MS mass spectrometry 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
n Nano (10-9) 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
nm nanometer (10-9) 
OD optical density 
OPG osteoprotegerin 
PAGE polyacrylamide gel electrophoresis 
PARP poly [ADP-ribose] polymerase 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI propidium iodide 
PS phosphatidylserine 
pSILAC pulsed stable isotope labeling by amino acids in cell culture 
PVDF polyvinylidene fluoride 
r recombinant 
RISC RNA induced signaling complex 
re reverse 
RNA ribonucleic acid 
rpm revolutions per minute 
RT room temperature 
SDS sodium dodecyl sulfate 
TB tuberculosis 
TEMED N,N,N',N'-tetramethyl-ethane-1,2-diamine 
TLR Toll like receptor 
TNFR tumor necrosis factor receptor 
TNFα tumor necrosis factor alpha 
TRAIL TNF-related apoptosis-inducing ligand 
Tris tris(hydroxymethyl)aminomethane 
TUNEL dUTP Western blot nick end labeling 
WB  
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1. Introduction 
1.1 MicroRNAs 
The controlled expression of genes is an essential feature of living eukaryotic cells 
controlled by several different mechanisms. MicroRNAs (miRNAs) are an abundant class of 
newly identified and highly conserved endogenous non-protein-coding short (~22 nt) RNA 
molecules that play an essential role in the regulation of cellular homeostasis (Bartel, 2004). 
miRNAs have been shown to play cardinal roles in biological processes including tissue 
development, stem cell differentiation, innate and adaptive immune responses (Hou et al, 
2009; Houbaviy et al, 2003; Judson et al, 2009; Lee et al, 1993; O'Connell et al, 2010; 
Taganov et al, 2007; Wang et al, 2008). Currently, the best characterized function of miRNAs 
is the fine tuning of gene activity at the post-transcriptional level by impairing gene 
expression. 
 
 
1.1.1 History  
The history of miRNAs started in the early years of last century´s decade when two 
independent groups discovered that a small RNA molecule named lin-4 was involved in 
Caenorhabditis elegans development by regulating the expression of lin-14, a gene 
responsible for temporal pattern formation (Ambros & Horvitz, 1987; Lee et al, 1993; 
Wightman et al, 1993). Although these reports did not include a precise mechanistic 
description of the studied phenomenon, two seminal observations for future miRNA research 
were made: lin-4 is not protein-coding and it contains antisense sequences complementary to 
a repeated motif in the 3´-untranslated region (3´-UTR) of the lin-14 mRNA. Despite these 
relevant results, it took seven years until let-7 was discovered as a small regulatory RNA 
highly conserved in a wide range of animal species and real interest in these novel class of 
molecules started to grow (Pasquinelli et al, 2000; Reinhart et al, 2000). This was evidenced 
one year later, in 2001, by publication of three groundbreaking reports on the identification of 
a large number of short RNAs similar to lin-4 and let-7 in different animal species. This was 
the first time that the term miRNA was coined to denominate this novel class of expression 
regulators (Lagos-Quintana et al, 2001; Lau et al, 2001; Lee & Ambros, 2001). Ever since, 
miRNAs have become subject of very intensive research. As of September 2009 more than 
10 000 miRNA sequences had been deposited in repository genomic databases and it was 
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estimated in-silico that miRNAs may represent up to 5% of all genes of an organism (Lim et 
al, 2003a; Lim et al, 2003b). Moreover, 30% of all human protein-coding genes are predicted 
to be regulated post-transcriptionally by miRNAs (Lewis et al, 2005).  
 
 
1.1.2 miRNA biogenesis  
Generation of functional miRNAs is a complex multi-enzyme process leading from 
long precursor molecules into ~22 nt long biologically active RNA molecules. MicroRNA 
genes are generally transcribed in the nucleus by RNA polymerase II (Pol II) in large primary 
miRNA transcripts (pri-miRNA) that undergo normal further processing i.e. 5´-capping, 3´-
polyadenylation or even splicing (Cai et al, 2004). These RNA molecules form specific 
hairpin-shaped stem-loop secondary structures and enter a multi-enzyme complex known as a 
microprocessor to be modified by the RNAse III enzyme Drosha and its co-factor, Pasha. 
This leads to the formation of a ~70 nt precursor miRNAs (pre-miRNA) with a 5´-phosphate 
and a 3´- 2 nt long overhang (Denli et al, 2004). Export of pre-miRNAs to the cytoplasm is 
performed by ras-related nuclear protein (RAN-GTP) and exportin 5 (XPO5) (Bohnsack et al, 
2004). Cytoplasmic pre-miRNAs are further processed by another RNAse III enzyme termed 
Dicer to generate a transient ~22 nt long double stranded miRNA (Hutvagner et al, 2001). 
This duplex is unwounded by helicases into two single strands, one of which is then loaded 
into the miRNA-associated multiprotein RNA-induced silencing complex (miRISC) which 
includes the Argonaute proteins and induces gene silencing (Schwarz et al, 2003) (Scheme 
1).  
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Scheme 1 Molecular mechanisms of miRNA biogenesis and function (Esquela-Kerscher & Slack, 2006) 
 
 
1.1.3 Mechanisms of miRNA-mediated gene regulation 
 
 In most cases miRNAs interact with their targets by base pairing to sequences located 
within the 3´-UTR of the mRNA. However, it has also been reported that miRNAs can exert 
their regulatory function by targeting sequences located in the 5´-UTR or coding sequence 
(cds) (Duursma et al, 2008; Forman et al, 2008; Lewis et al, 2005; Spizzo et al; Zhou et al, 
2009). Currently, three features important for miRNA-target interactions have been identified 
bioinformatically and experimentally. First, nucleation of miRNA:mRNA interactions by 
contiguous base pairing of miRNA nucleotides 2 to 8 ( also known as “seed” region) (Doench 
& Sharp, 2004). Second, bulges or mismatches must be present in the central region of the 
miRNA-mRNA duplex (Watanabe et al, 2006). The third rule is that there must be good 
complementarity to the miRNA 3´ half to stabilize the interaction (Brennecke et al, 2005)  
(Scheme 2). Other variables that favor the efficiency of miRNA-mediated silencing are an 
AU-rich region and a position close to the poly(A) tail or the termination codon (Grimson et 
al, 2007; Nielsen et al, 2007) (Scheme 2). Finally, in animal transcripts imperfectly paired 
target sites for the same miRNA often occur multiple times within the same mRNA. This 
multiplicity of binding regions correlates directly to the magnitude of gene expression 
repression (Doench & Sharp, 2004).  
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Scheme 2. Molecular principles and rules governing miRNA-mRNA interactions (Filipowicz et al, 2008) 
 
Depending on the degree of complementarity between the miRNA and its target, it 
can direct RISC to down-regulate gene expression by either of two post-transcriptional 
mechanisms: translational arrest or mRNA cleavage (Hutvagner & Zamore, 2002). 
Translational arrest is mediated by molecular mechanisms taking place at two different stages 
during protein biosynthesis (Eulalio et al, 2008): 
 
- Initiation mechanisms: miRNAs and RISC can interfere with very early steps of 
mRNA translation. For instance, Argonaute proteins compete with initiation factors 
for binding to the cap structure of mRNAs (Kiriakidou et al, 2007) and, they can 
recruit inhibitory factors that prevent the joining of the 40 and 60S ribosomal units 
(Chendrimada et al, 2007).   
 
- Post-initiation mechanisms: miRNAs can block translation elongation by promoting 
premature ribosomal dissociation (“ribosome drop-off”) (Maroney et al, 2006; 
Petersen et al, 2006). Moreover, a third model proposes that the nascent polypeptide 
chain might be degraded co-translationally (Nottrott et al, 2006). 
 
In eukaryotes, miRNA-mediated mRNA degradation can follow two pathways, both  
of which are initiated by gradual shortening of the mRNA poly(A) tail (Filipowicz et al, 
2008). This can lead to further 3´5´decay, which is catalyzed by the exosome or, to 
removal of the cap followed by 5´3´ degradation (Behm-Ansmant et al, 2006; Giraldez et 
al, 2006).  
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1.2 Apoptosis 
Apoptosis is a form of active programmed cell death (PCD) inherently determined 
and strictly regulated, that plays an important role for a plethora of processes in multicellular 
organisms (Kerr et al, 1972). Apoptosis occurs normally during development, aging and as a 
homeostatic mechanism to maintain equilibrium between cell populations in tissues and 
organs. It also occurs as a defense mechanism such as in immune reactions or when cells are 
severely damaged by disease or cytotoxic agents. Cells undergoing apoptosis are 
characterized by well defined morphological and biochemical changes such as rounding-up 
of the cell, retraction of pseudopodes, reduction of cellular volume, classically little or no 
ultrastructural modifications of cytoplasmic organelles, caspase activation, decay of 
mitochondrial transmembrane potential (ΔΨm), activation of pro-apoptotic molecules, 
chromatin condensation, mitochondrial membrane permeabilization (MMP), nuclear 
fragmentation, and membrane blebbing (Kroemer et al, 2009). Another biochemical feature is 
the expression of cell surface markers such as phosphatidylserine (PS) that result in the early 
phagocytic recognition of apoptotic cells by adjacent phagocytes, permitting quick clearance 
and minimal compromise to the surrounding tissue (Bratton et al, 1997; Elmore, 2007). This 
process of controlled cellular suicide can be triggered by extracellular and intracellular 
stimuli, both of which result in the activation of specific, yet partially overlapping molecular 
mechanisms. 
 
 
1.2.1 Extrinsic apoptotic pathway 
The extrinsic signaling pathways that initiate apoptosis involve transmembrane 
receptor-mediated interactions. These encompass death receptors (DRs) which represent a 
group of extracellular membrane-bound molecules responsible for sensing and transducing 
exogenously derived pro-apoptotic signals. DRs, including the tumor necrosis factor receptor 
1 and 2 (TNFR1/2), Fas/APO1 (CD95) and TNF-related apoptosis-inducing ligand (TRAIL) 
receptors DR4 and DR5, belong to the TNF superfamily and share similar cysteine-rich 
extracellular domains and a common structurally conserved 80 amino-acid long cytoplasmic 
death domain (DD) (Aggarwal, 2003; Ashkenazi & Dixit, 1998). Upon cognate ligand 
binding, DRs oligomerize via their DD giving rise to a scaffold for the recruitment of several 
adaptor and signaling molecules (Grimm et al, 1996; Hsu et al, 1995). At this death inducing 
signaling complex (DISC), initiator caspases such as caspase 8 or 10 (CASP8/10) get 
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activated by means of autocatalytic cleavage (Kischkel et al, 1995). Once triggered, initiator 
caspases launch the execution phase of the death signal by processing effector caspases, like 
CASP3, 6 or 7, to their active forms (Scheme 3).  
 
 
Scheme 3. Apoptosis signaling through death receptors as exemplified by Fas/FasL signaling system. Modified 
after (Igney & Krammer, 2002) 
 
As a consequence of this released proteolytic activity, key intracellular factors, also 
known as death substrates, are degraded. Cleavage of nuclear lamins is involved in chromatin 
condensation and nuclear shrinkage (Rao et al, 1996). Proteolysis of the inhibitor of caspase 
activated deoxyribonuclease (ICAD) causes the release of the endonuclease, which travels to 
the nucleus to fragment DNA (Enari et al, 1998). Cleavage of cytoskeletal proteins such as 
actin, plectin, Rho kinase 1 (ROCK1) and gelsolin leads to cell fragmentation, blebbing and 
the formation of apoptotic bodies (Chen et al, 1996; Kothakota et al, 1997; Sebbagh et al, 
2001; Stegh et al, 2000). After execution of the apoptotic program the remains of the dying 
cell are engulfed by phagocytes (Savill & Fadok, 2000). 
 
 
1.2.2 Intrinsic apoptotic pathway 
 Intrinsic apoptosis is triggered by several conditions of intracellular stress, such as 
reactive oxygen species, DNA damage, hypoxia and Ca2+ overload. All these stimuli 
disembogue in changes of the mitochondrial membrane that lead to the opening of the 
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mitochondrial permeability transition pore (MPT). Consequently, ΔΨm is lost and proteins 
from the mitochondrial intermembrane space (IMS) are released into the cytosol (Scheme 4), 
where they promote cell death by multiple mechanisms (Kroemer et al, 2007).  
 
 
Scheme 4. Mitochondrial (intrinsic) apoptosis pathway. Modified after (Galluzzi et al, 2009). 
Released proteins include cytochrome c (CYTC), second mitochondria-derived activator of 
caspases/direct inhibitors of apoptosis proteins (IAP)-associated binding protein with low pI 
(SMAC/DIABLO), the serine protease high temperature requirement protein A2 
(HtrA2/OMI), apoptosis-inducing factor (AIF), endonuclease G (EndoG) and caspase 
activated deoxyribonuclease (CAD) (Du et al, 2000; Enari et al, 1998; Li et al, 2001; Liu et 
al, 1996a; Susin et al, 1996; van Loo et al, 2002). CYTC oligomerizes with apoptotic 
peptidase activating factor 1 (APAF1), dATP and CASP9 forming the apoptosome. In this 
complex caspase-9 is activated by oligomerization and can then process other caspases, such 
as caspase-3, thus committing the cell to suicide (Zou et al, 1999). SMAC/DIABLO and 
HtrA2/OMI are reported to promote apoptosis by antagonizing the activity of members of the 
IAP family (van Loo et al, 2002). Cytoplasmic AIF, EndoG and CAD contribute to DNA 
fragmentation and subsequent chromosomal condensation (Enari et al, 1998; Joza et al, 2001; 
Li et al, 2001). MPT independent MMP is regulated by B-cell lymphoma 2 (BCL2) family 
members, which are characterized by BCL2 homology (BH) domains (Wang & Youle, 
2009). The Bcl-2 family can be subdivided into anti-apoptotic members such as BCL2, BCL-
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XL and BCL-w and pro-apoptotic species such as BCL2-associated X protein (BAX), BCL2-
antagonist/killer 1 (BAK), BCL2-associated agonist of cell death (BAD), BH3 interacting 
domain death agonist (BID) and NOXA (Yip & Reed, 2008). It is thought that pro-apoptotic 
Bcl-2 family members form channels in the outer mitochondrial membrane through which 
apoptogenic proteins of the IMS are released (Korsmeyer et al, 2000). 
 
 
1.2.3 Crosstalk between apoptosis signalling pathways 
There is also crosstalk between the extrinsic and intrinsic apoptosis pathways. Death 
receptors can activate the cell-intrinsic pathway by CASP8-mediated cleavage of BID. The 
resulting truncated BID (tBID) interacts with the pro-apoptotic BAX and BAK, leading to 
their oligomerization and insertion in the outer mitochondrial membrane (Eskes et al, 2000; 
Wei et al, 2000). This results in release of mitochondrial CYTC and SMAC/DIABLO, as 
well as subsequent activation of CASP9 and 3 and amplification of apoptosis induction 
through the cell-extrinsic pathway. In some cell types, death-receptor engagement commits 
cells to apoptotic death. In other cell types, apoptosis may require amplification of the death-
receptor signal by the cell-intrinsic pathway (Scaffidi et al, 1999b). 
 
Scheme 5. Crosstalk between DR-mediated and intrinsic apoptosis. Modified after (Ashkenazi, 2002) 
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1.2.4 Negative regulators of apoptosis 
 Cells possess a complex set of mechanisms regulating their responsiveness to DR 
ligands and intrinsic apoptosis inducers. While most TNFR-superfamily (TNFRSF) members 
function as transmembrane signal transducers that respond to ligand binding, some do not 
signal and act as decoys that compete for the interaction of cognate ligands with their 
signalling receptors (Ashkenazi, 2002). Table 1 lists some examples of decoy receptors 
(DcRs). 
 
Table 1. Death ligand DcRs 
Ligand DcR Description Reference 
 
Osteoprotegerin (OPG) 
 
Soluble decoy receptor that binds to TRAIL 
and protects from TRAIL-induced apoptosis 
 
(Emery et al, 1998) 
 
DcR1 
 
DcR1 lacks a cytoplasmic DD and is attached 
to the plasma membrane through a 
glycophospatidylinositol anchor  
(Sheridan et al, 1997)  
TRAIL 
 
DcR2 
 
 
DcR2 is a transmembrane protein with a 
truncated DD in its cytoplasmic tail that is 
unable to signal apoptosis 
 
 
(Marsters et al, 1997) 
 
 
FasL 
 
 
DcR3 
 
 
DcR3 encodes a soluble protein that contains 
signal sequence but no transmembrane domain 
 
 
(Pitti et al, 1998) 
 
 
Furthermore, cells must protect themselves from inappropriate activation of apoptosis 
to ensure survival. To achieve this, they express a whole array of anti-apoptotic factors that 
block the initiation of the cytotoxic response triggered by the extrinsic or intrinsic pathway 
mainly at two critical levels:  
 
- Apoptosis inhibition at the caspase level: IAPs are a broadly conserved family of anti- 
apoptotic proteins that block cell death, in part, by directly inhibiting the activation 
pathways of CASP3, 7 and 9. Over-expression of IAPs prevents apoptosis induced by 
a wide variety of stimuli, including TNFα, FasL, staurosporine, etoposide and growth 
factor withdrawal (Deveraux et al, 1998). Eight mammalian IAPs are known at 
present: X chromosome-linked IAP (XIAP), cellular IAP1 and IAP2 (cIAP1/2), 
neuronal apoptosis inhibitory protein (NAIP), SURVIVIN, BRUCE, LIVIN and 
testis-specific IAP (Ts-IAP) (Mannhold et al, 2010; Schimmer, 2004). The criteria for 
membership in this IAP family are the presence of a BIR domain and the ability to 
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inhibit apoptosis. BIR domains are known to be critical for the inhibitory activity of 
IAP proteins by providing an interaction site for caspases. Cellular FLICE-like 
inhibitory proteins (cFLIPs) represent another group of highly conserved anti-
apoptotic proteins that act by impairing caspase activation. FLIPs function as 
dominant-negative inhibitors of CASP8 by using a DD to block the recruitment of 
proCASP8 to the DISC. As a result, CASP8 subsequent processing and activation is 
blocked and the pro-apoptotic signal is impaired (Budd et al, 2006).   
- Apoptosis inhibition at the mitochondrial level: As mentioned previously (see 1.2.2) 
the mitochondria-associated BCL2 family of proteins includes anti-apoptotic 
members such as BCL2, BCL-XL and BCL-w. Currently, the mechanisms by which 
members of the BCL2 family regulate apoptosis have not been completely 
understood. However, a physical interaction between pro- and anti-apoptotic BCL2 
family members facilitates to circumvent the cell death process. Competition between 
homodimerization and heterodimerization of pro- and anti-apoptotic BCL2 family 
members may play a pivotal role in their capacity to induce or prevent cell death by 
impairing the swelling of mitochondrial membrane, maintaining the mitochondrial 
metabolism, limiting the effect of reactive oxygen species and regulating the MTP 
pore. Ultimately, all these mechanisms hinder the release of pro-apoptotic factors 
from the mitochondria which responsible for initiating the apoptotic cascade (Bortner 
& Cidlowski, 2002). 
 
 
1.2.5 miRNA-mediated regulation of apoptosis 
Several lines of evidence point to miRNAs as important apoptosis regulatory factors. 
To date, no less than 30 individual miRNAs have been experimentally demonstrated to 
regulate apoptosis. This number is expected to increase quickly since in-silico analysis 
predicts ~93% of all known vertebrate miRNAs to have at least one target gene related to cell 
death and survival (Yang et al, 2009). Depending on the nature of the targeted genes, 
miRNAs can be catalogued as pro- or anti-apoptotic. However, experimental evidence has 
shown that the effect of a given miRNA on cell death may be strongly influenced by the 
cellular context (Yang et al, 2009). So far the role of miRNAs in the regulation of apoptosis 
has been best characterized in the context of DR-independent signaling. One prominent 
example of an anti-apoptotic miRNA is miRNA-21, which is the most consistently up-
Introduction 
11 
 
regulated miRNA across many cancer types (Wang & Lee, 2009). MiRNA-21 knockdown 
resulted in an impaired cell viability of cultured glioblastoma cells and this correlated with 
increased CASP3 and 7 activity and stronger TUNEL staining (Chan et al, 2005; Corsten et 
al, 2007). MiRNAs can also have strong pro-apoptotic features like for instance miRNA-29b 
which targets the anti-apoptotic BCL2-family member gene myeloid cell leukemia sequence 
1 (MCL1) (Mott et al, 2007). Table 2 presents additional examples of miRNAs with known 
pro- or anti-apoptotic properties. 
 
Table 2. Examples of pro- and anti-apoptotic miRNAs 
Name Effect Target gene(s) Reference 
 
miRNA-34a 
 
E2F3 
 
(Welch et al, 2007) 
 
miRNA-15a and 16-1 
 
BCL2 
 
(Cimmino et al, 2005) 
 
miRNA-1 
 
HSP60/70 
 
(Xu et al, 2007) 
 
let-7 
 
 
 
 
pro-apoptotic 
 
 
 
 
 
RAS/NF2 
 
 
(Johnson et al, 2005; Meng et al, 2007) 
 
 
miR-27a 
 
 
 
ZBTB10/RINZF 
 
(Scott et al, 2006) 
 
miRNA-14 
 
 
 
DRICE 
 
(Xu et al, 2003) 
 
miRNA-155 anti-apoptotic 
 
TP53INp1 
 
(Gironella et al, 2007) 
 
miRNA-221/222 
 
 
 
ER-α 
 
(Zhao et al, 2008) 
    
 
 
1.3 Pathogen recognition during innate immunity 
In the course of evolution the mammalian immune system developed into a complex 
array of cellular and molecular components and processes that, most times, effectively shelter 
the organism from diseases caused by invading pathogens such as bacteria, viruses, fungi or 
parasites. It also plays an important role during the control of transformed “malignant self 
cells” that may become harmful or even lethal for the organism (Wolska et al, 2009). 
Protection is provided by layered defense mechanisms of increasing specificity {Murphy, 
2008 #2616}. The first shield consists of unspecific physical barriers such as skin, epithelial 
surfaces of respiratory, urinary and gastrointestinal tracts, mucus and saliva. Pathogens 
breaching these are first confronted with an immediate non-specific “pre-programmed” 
defense response provided by cells of the innate immune system. If infection persists, the 
adaptive immune system is activated and provides a third layer of pathogen-specific long-
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lasting protection. Despite profound differences between innate and adaptive immunity, both 
processes are tightly intertwined and, adequate immune function relies on their synergistic 
anti-pathogenic action (Dorhoi & Kaufmann, 2009; Murphy et al, 2008b). 
 
The innate immune system is characterized by its germline-encoded ability to 
discriminate between self and non self molecules. Innate immune cells such as dendritic cells 
(DCs), macrophages and neutrophils, express various pattern-recognition receptors (PRRs) 
which recognize signature molecules of pathogens. These signature molecules are known as 
pathogen-associated molecular patterns (PAMPs), although they are also present on non-
pathogenic microorganisms (Akira, 2009; Janeway & Medzhitov, 2002). PAMPs are well 
suited to innate immune recognition for three main reasons. First, they are invariant among 
microorganisms of a given class. Second, they are products of pathways that are unique to 
microorganisms. Third, they have essential roles in microbial physiology, limiting the ability 
of the microorganisms to evade innate immune recognition through adaptive evolution of 
these molecules (Medzhitov, 2007). Hitherto, several classes of PRRs such as Toll-like 
receptors (TLRs), Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and 
Nucleotide-binding oligomerization domain (NOD)-like receptor (NLRs) have been 
identified. PRRs recognize different PAMPs in various cell compartments (Table 1.).  
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Table 3. Localization and specificity of selected human PRRs 1 
Family Name Location PAMPs recognized 
 
TLR1/2 
 
 
Plasma membrane 
(cell surface) 
 
 
Triacyl lipopeptides (bacteria and mycobacteria) 
 
TLR2 
 
Plasma membrane 
(cell surface) 
 
Peptidoglycan (gram-positive bacteria), LAM 
(mycobacteria), Hemagglutinin (measles virus), 
phospholipomannan (Candida), Glycosylphosphophatidyl 
inositol mucin (Trypanosoma) 
 
TLR3 
 
Endosome 
 
ssRNA virus (WNV), dsRNA virus (reovirus), RSV 
 
TLR4 
 
Plasma membrane 
(cell surface) 
 
LPS (gram-negative bacteria), Mannan (Candida), 
Glycoinositolphospholipids (Trypanosoma), envelope 
proteins (RSV) 
 
TLR5 
 
Plasma membrane 
(cell surface) 
 
Flagellin (flagellated bacteria) 
 
TLR6/2 
 
Plasma membrane 
(cell surface) 
 
Diacyl lipopeptides (mycoplasma), LTA (streptococus), 
Zymosan (Saccharomyces) 
 
TLR7 
 
Endosome 
 
ssRNA viruses (VSV, influenza virus) 
 
TLR8 
 
Endosome 
 
ssRNA from RNA virus 
 
TL
R
s 
TLR9 
 
Endosome 
 
dsDNA viruses (HSV), CpG motifs from bacteria and 
viruses, Hemoyoin (Plasmodium) 
 
 
RIG-I 
 
 
Cytoplasm 
 
 
Cytoplasmic 5´-triphosphate dsRNA (flavivirus, HCV) 
  
R
LR
s 
 
MDA5 
 
Cytoplasm 
 
Cytoplasmic dsRNA (picornavirus, ECMV) 
 
 
NOD1 
 
 
Cytoplasm 
 
 
g-D-glutamyl-meso-diaminopimelic acid (gram-negative 
and gram-positive bacteria) 
 
NOD2 
 
Cytoplasm 
 
muramyl dipeptide (gram-negative and gram-positive 
bacteria) 
 
IPAF 
 
Cytoplasm 
 
Flagellin (flagellated bacteria) 
 
N
LR
s 
NALP3 
 
Cytoplasm 
 
Bacterial RNA (L. monocytogenes; S. aureus) 
 
1Based on (Chen et al, 2009; Kawai & Akira, 2009; Kumar et al, 2009; Nakhaei et al, 2009) 
LAM, Lipoarabinomannan; WNV, West Nile Virus; RSV, Respiratory syncitial virus; LPS, 
Lipopolysaccharide; LTA, Lipoteichoic acid; VSV, vesicular stomatitis virus; HSV, Herpes simplex virus and 
CpG, Cytidine-phosphate-guanosine.  
 
PRR activation triggers the release of inflammatory cytokines, chemokines and type I 
interferons (IFNs). In the case of TLR signaling, ligand recognition leads to the recruitment 
of adaptor molecules such as myeloid differentiation primary response gene 88 (MyD88), 
Toll-interleukin 1 receptor domain-containing adaptor (TIRAP), Toll-interleukin 1 receptor 
domain-containing adapter protein inducing IFN-beta (TRIF) and translocation associated 
membrane protein 1 (TIRAP). All these adaptors share a common structural feature 
denominated Toll/Interleukin-1 receptor (TIR) domain and their engagement leads to 
activation of specific signaling pathways and transcription factors like nuclear factor 'kappa-
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light-chain-enhancer' of activated B-cells (NF-κB) and members of the interferon regulatory 
factor (IRF) family. Furthermore, recruitment of TIR adaptor molecules also results in the 
activation of mitogen-activated protein kinases (MAPKs) such as p38, c-Jun N-terminal 
kinases (JNKs) and extracellular-signal regulated kinases (ERKs) leading to the activation of 
the transcription regulator activator protein 1 (AP1). These transcription factors are 
responsible for inducing the expression of pro-inflammatory effector molecules (Beutler, 
2009b; Kumar et al, 2009; Rasmussen et al, 2009) (Scheme 6). RLRs rely on different 
signaling mechanisms to activate the inflammatory response. Upon recognition of dsRNA, 
RIG1 or melanoma differentiation associated protein-5 (MDA5) are recruited by the adaptor 
IFN-β promoter stimulator 1 (IPS1) to the outer membrane of the mitochondria leading to the 
activation of several transcription factors including IRF3, IRF7 and NF-κB (Kawai et al, 
2005). IRF3 and IRF7 control the expression of type I IFNs, while NF-κB regulates the 
production of inflammatory cytokines (Scheme 6).  
 
 
Scheme 6. Molecular signaling pathways triggered by PAMPS through PRRs (source: www.invivogen.com) 
 
Finally, PAMP sensing through NLRs like nucleotide-binding oligomerization 
domain containing 1 or 2 (NOD1/2) involves the recruitment of signaling molecules 
including receptor-interacting protein 2 (RIP2) or caspase recruitment domain family member 
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9 (CARD9). These are responsible for the transmission of the signal that leads to the final 
activation of NF-κB and AP1 (Scheme 6).  
 
PRR mediated secretion of inflammatory cytokines and chemokines is of central 
importance since it modulates and controls not only the innate immunity but also the adaptive 
immune response against invading pathogens. Cytokines like interleukin 1 beta (IL1β), 
interleukin 6 (IL6) or tumor necrosis factor alpha (TNFα) contribute in an autocrine and 
paracrine manner to activate the surrounding vascular epithelium at the site of infection, to 
prime lymphocytes and to recruit neutrophils, basophils and T cells. Chemokines are 
chemoattractant molecules that function by recruiting leukocytes, monocytes, neutrophils and 
other effector cells to the site of infection. Some prominent examples include interleukin 8 
(IL8) and chemokine (C-C motif) ligand 5 (CCL5 also known as RANTES). In case of viral 
infections also type I IFNs i.e. IFN-alpha and beta (IFNα/β) are produced and released by 
infected cells. These contribute mainly through three different mechanisms to the inhibition 
of viral replication. First, they induce genes that impair the expression of viral transcripts and 
degrade them. Second, IFNs increase the ability of infected cells to present viral peptide 
fragments via major histocompatibility class I (MHCI) pathway. Finally, IFNs are very potent 
activators of natural (NK) killer cells that can kill virus infected cells selectively. As 
mentioned previously, the effector molecules produced during innate immune responses are 
not only important because of their direct anti-pathogenic effects, but also because they 
contribute to the establishment and modulation of antigen-specific adaptive immunity. One 
example of this crosstalk between innate and adaptive immunity deals with the ability of 
PRR-induced cytokines to enhance antigen presentation by professional antigen presenting 
cells (APCs). The adaptive immune response is dependent on co-stimulatory surface 
molecules, including CD40, CD80 and CD86, which are expressed by professional antigen-
presenting cells, including macrophages and DCs cells. These molecules help to generate a 
mitogenic response within T cells that are exposed to antigen in the context of MHCI and II 
proteins. It is now clear that the key event in up-regulation of co-stimulatory molecules is the 
activation of a type I IFN response mediated by PPRs (Beutler et al, 2006; Hoebe et al, 2003).  
 
Given the pivotal importance of PRR-mediated signaling for both innate and adaptive 
immunity, the molecular mechanism responsible for the pro-inflammatory signals must be 
strictly regulated. In fact, uncontrolled regulation of TLR-mediated signaling may lead to 
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excessive or persistent inflammation and severe immune pathology to the host (Manicassamy 
& Pulendran, 2009). Several diseases including septic shock, autoimmunity, atherosclerosis, 
metabolic syndrome and gastric cancer have been linked to chronic or acute inflammatory 
responses (Beutler, 2009a; Karin et al, 2006). To date, several negative regulators of TLR-
mediated inflammatory response have been identified. Notably, most of these molecules 
function by providing negative feedback to the signaling cascades, since they are induced 
upon TLR activation and impair the response at multiple levels. Some examples of negative 
regulators include phosphatidylinositol-3 kinase (PI3K), suppressor of cytokine signaling 1 
(SOCS1) and proteins such as IRAK-M und A20 (Boone et al, 2004; Dalpke et al, 2008; 
Fukao et al, 2002; Kobayashi et al, 2002). The relevance of these mechanisms is underlined 
by the fact that mutations affecting the expression of these genes are related to human health 
disorders like early-onset persistent asthma, coronary artery disease in type 2 diabetes and 
adult asthma (Balaci et al, 2007; Boonyasrisawat et al, 2007; Harada et al, 2007).  
 
 
1.3.1 miRNA-mediated regulation of innate immune responses 
 Inflammatory responses to invading pathogens involve the induction of numerous 
genes, a process that must be tightly regulated to achieve pathogen clearance and at the same 
time avoid consequences of dysregulated gene expression such as uncontrolled inflammation 
and cancer (Sonkoly et al, 2008). The involvement of miRNAs in the fine tuning of innate 
immunity has been a field of intensive research. This has led to the identification of miRNAs 
as important regulators of monocyte differentiation and maturation, granulocyte proliferation 
and activation, pathogen sensing, inflammatory responses and antiviral immunity (Fontana et 
al, 2007; Jing et al, 2005; Johnnidis et al, 2008; Pedersen et al, 2007; Taganov et al, 2006). In 
macrophages it has been shown that activation of TIRs and TNFα receptor results in rapid 
expression of host miRNAs such as miRNA-9, 146a and 155 (Bazzoni et al, 2009; O'Connell 
et al, 2007; Perry et al, 2008; Taganov et al, 2006). As revealed by target gene analysis, these 
impair the expression levels of proteins involved in the pro-inflammatory signaling pathway 
including TNF receptor-associated factor 6 (TRAF6) (miRNA-146a), interleukin-1 receptor-
associated kinase 1 (IRAK1) (miRNA-146a), NF-κB1 (miRNA-9), NF-κB inhibitor epsilon 
(IKKε) (miRNA-155) and mitogen-activated protein kinase kinase kinase 7 interacting 
protein 2 (TAB2) (miRNA-155) (Bazzoni et al, 2009; Ceppi et al, 2009; Taganov et al, 2006; 
Xiao et al, 2009). MiRNA-mediated down-regulation of these genes allows cells to control 
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their activation status by dampening the signaling pathways that govern the expression of 
pro-inflammatory cytokines. Innate immunity-associated miRNAs perform also functions 
other than controlling the acute response to invading pathogens (Scheme 7).  
 
 
Scheme 7. Role of microRNAs in the innate immune response. Modified after (Lindsay, 2008) 
 
In humans, analysis of monocyte differentiation showed that stimulation of cord blood 
CD34+ with macrophage-colony stimulating factor (M-CSF) resulted in reduced expression 
of miRNA-17-5p, 20a and 106a. Further experiments revealed that decreased expression of 
these miRNAs allowed higher levels of their target protein acute myeloid leukemia-1 
(AML1) to occur. AML1 is a transcription factor responsible for induction of the M-CSF 
receptor, IL13 and granulocyte macrophage-colony stimulating factor (GM-CSF) (Fontana et 
al, 2007; Tsitsiou & Lindsay, 2009). Interestingly, miRNA-155 may also drive the expansion 
of granulocyte and macrophage populations. Indeed long-term expression of miRNA-155 in 
hematopoietic stem cells and engraftment into lethally irradiated mice resulted in a phenotype 
similar to acute myeloid leukemia (AML) (O'Connell et al, 2008) (Scheme 7). An additional 
well-studied example of the importance of miRNA-mediated regulation of the innate immune 
system is provided by miRNA-223. Expression profiling has shown that miRNA-223 is 
transcribed in myeloid cells in the bone marrow and that its increased expression is relevant 
for the differentiation of precursor cells into granulocytes (Chen et al, 2004; Fazi et al, 2005; 
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Johnnidis et al, 2008). It was suggested that miRNA-223 exerts its role through the down-
regulation of genes such as myeloid ELF1-like factor (MEF2c), insulin-like growth factor 
receptor (IGFR) and nuclear factor I-A (NFI-A) (Fazi et al, 2005; Johnnidis et al, 2008) 
(Scheme 7). Providing further evidence for the multiple roles of miRNAs, neutrophils from 
miRNA-223 knockout mice showed enhanced oxidative burst and killing of Candida 
albicans. Moreover, these mice spontaneously developed inflammatory lung pathology and 
exhibited exaggerated tissue destruction after endotoxin challenge. This suggests that 
miRNA-223 can also act as a negative regulator of the inflammatory response (Johnnidis et 
al, 2008). 
 
 
1.4 Tuberculosis 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of human 
tuberculosis (TB), kills nearly two million people annually and has been a major health threat 
for centuries (Parida & Kaufmann, 2010; World Health Organization., 2009). TB is a disease 
of poverty with the highest incidence rates occurring in low income and lower middle-income 
countries. Despite its importance as a global health threat, the most recent TB drug was 
developed decades ago; the standard diagnostic technology used in developing countries is 
more than 100 years old; and the BCG vaccine, with almost no protective effect in adults, 
was introduced in 1921 (Aagaard et al, 2009; Murphy et al, 2008a). In the post-genomic era, 
innovative tools that help us win the fight against this terrifying disease are urgently needed.  
 
 
1.4.1 History and biology 
TB is a millennial disease that has affected and shaped human civilizations since their 
very early beginnings. As demonstrated by palaeopathologic studies, Neolithic settlements 
from 9250-8160 years ago, around the time of the first great transition from hunter-gatherers 
to a settled agriculture-based lifestyle, and predynastic Egyptians (3500-2650 B.C.) suffered 
the inclemency of TB (Hershkovitz et al, 2008; Zink et al, 2001). Accordingly, numerous 
descriptions of TB are found in ancient texts (Daniel, 2006). The first description of M. 
tuberculosis as the causative agent of human TB was by Robert Koch on March 24th, 1882. 
His groundbreaking discovery was honored with the Nobel Prize in physiology or medicine 
in 1905 (Kaufmann & Schaible, 2005). Thereafter, further advancements in the fight against 
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TB were achieved. By 1921, Albert Calmette and Camille Guérin developed a viable 
attenuated vaccine. In 1943 Selman A. Waksman identified Streptomycin as the first 
antituberculous drug, opening the window for chemotherapeutic treatment of the disease 
(Kaufmann, 2005; Waksman, 1954). Despite these and other scientific breakthroughs in TB 
research, difficulties associated with the chemotherapeutic treatment, a vaccine that protects 
children but not adults, the appearance of human immunodeficiency virus (HIV) and the 
advent of drug-resistant strains kept TB as an ongoing threat. In 1993, the WHO declared TB 
as global emergency facing and accepting the fact that there is more TB in the world today 
that at any other time in history.  
 
M. tuberculosis is a slowly growing obligate aerobe bacterium. One central hallmark 
of this human pathogen is its cell envelope which contains an additional layer beyond the 
peptidoglycan that is exceptionally hydrophobic and rich in unusual lipids, glycolipids and 
polysaccharides (Brennan, 2003). In 1998 the sequencing of the complete M. tuberculosis 
genome revealed a very high guanine and cytosine content and ~ 4000 genes, from which a 
significant portion is devoted to the production of enzymes involved in lipogenesis and 
lipolysis (Cole et al, 1998). Importantly, several lines of evidence have demonstrated that this 
enhanced lipid metabolism is of crucial importance for the manipulation of the host cells 
during infection (Guenin-Mace et al, 2009).  
 
In TB, the lung is typically the port of entry and site of active disease although 
virtually all other organs can be afflicted (Kaufmann, 2006). Infection occurs via inhalation 
of droplets containing bacilli that are released by individuals with active pulmonary TB. In 
the lung, inhaled M. tuberculosis is ingested by resident alveolar macrophages and DCs. 
Inside these cells bacilli block the phagosome maturation by interrupting acidification and 
lysosome fusion, which creates a protected niche in the cell for bacterial replication 
(Armstrong & Hart, 1971). Infected phagocytes serve as Trojan horses that transport 
mycobacteria to the draining lymph nodes, were presumably secreted proteins such as early 
secreted antigen for T cells (ESAT6) and antigen 85 (Ag85) are presented to CD4+ T cells 
(Kaufmann & McMichael, 2005). Infected macrophages that remain in the lung induce a 
local pro-inflammatory response that leads to the recruitment of mononuclear cells from 
neighboring blood vessels. They also interact with activated antigen-specific T cells giving 
rise to the formation of a productive granulomatous lesion which is composed of infected 
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macrophages surrounded by foamy macrophages and other mononuclear phagocytes mantled 
by a layer of lymphocytes in association with a fibrous cuff of collagen and other 
extracellular matrix components that delineate the periphery of the structure (Russell, 2007) 
(Scheme 8).  
 
 
Scheme 8. Granuloma formation after airborne M. tuberculosis infection. Modified after (Russell, 2007) 
 
The granuloma deprives the arrested mycobacteria of oxygen and nutrients forcing the 
microbes to survive in a state of dormancy. Granuloma formation takes place in over 90% of 
infection cases and is a hallmark of the so called “containment” or “latent” phase in which 
there are no disease symptoms and the host is not contagious for others (Kaufmann & 
McMichael, 2005). Latent infection can be maintained for the lifetime of the host. 
Reactivation occurs in 5 to 10% of infected persons, and can be triggered by 
immunosuppression due to age, corticosteroids, malnutrition or other factors (Flynn, 2004). 
Consequently, co-infection with HIV increases the risk of developing TB several 100-fold 
(Kaufmann & McMichael, 2005). When individuals with active pulmonary TB cough, 
sneeze, speak, or spit, they expel infectious aerosol droplets. A single sneeze can release up 
to 40 000 droplets (Cole & Cook, 1998). Importantly, each single droplet represents 
significant transmission risk, since TB infectious dose is very low and inhaling less than ten 
bacteria may cause an infection (Behr et al, 1999; Nicas et al, 2005). 
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1.4.2 Innate immune response of the host to TB 
 As mentioned previously (see 1.5.1), phagocytic cells play a key role in the initiation 
and direction of immune responses against mycobacteria. A number of receptors are crucial 
for the recognition of M. tuberculosis by phagocytes. These include the complement 
receptors, mannose receptor (MR), DC-specific intercellular adhesion molecule-3 (ICAM3)-
grabbing non-integrin (DC-SIGN), surfactant protein A (SP-A) receptor, the class A 
scavenger receptor and mannose-binding lectin (MBL) (Berrington & Hawn, 2007). Whereas 
human macrophages use MR and complement receptor 3 (CR3) for binding to M. 
tuberculosis, DCs primarily use DC-SIGN (Kang et al, 2005; Schlesinger, 1993; Tailleux et 
al, 2003). Also TLRs have been associated with the recognition of M. tuberculosis. Several 
in-vitro studies have provided evidence for TLR1, 2, 4, 6 and 9 as important sensors of 
tubercle bacilli (Heldwein & Fenton, 2002; Means et al, 1999; Underhill et al, 1999). 
Mycobacterial TLR ligands include lipoproteins (TLR2), mycolylarabinogalactan-
peptidoglycan complex (TLR2), lipids (TLR2), LAM (TLR2), triacylated lipopetides 
(TLR1), diacylated lipopetides (TLR6), 19-kDa lipoprotein (TLR1) and a non-canonical 
TLR4 ligand (Berrington & Hawn, 2007). The in-vivo significance of individual TLRs has 
been more difficult to demonstrate. In the murine TB model, several studies have shown that 
mice deficient in MyD88 are highly vulnerable to intranasal TB infection and die due to 
unrestrained bacterial growth (Fremond et al, 2004; Scanga et al, 2004; Sugawara et al, 
2003). On the other hand, the data concerning mycobacterial challenge of TLR2, 4, 9 single, 
TLR2/9 double and TLR2/4/9 triple knockout mice has been less conclusive, ranging from 
normal to increased susceptibility (Korbel et al, 2008). In humans, several genetic studies 
indicate that TLR pathway variants may influence susceptibility to disease. These include 
polymorphisms in the TIR domain of TLR2 and TIR domain containing adapter protein 
(TIRAP) (Khor et al, 2007; Ogus et al, 2004).  
 
 M. tuberculosis recognition by macrophages results in the induction of a large number 
of cytokines, some of which have been demonstrated to be essential for the proper control of 
TB. TNFα is strongly produced after exposure of monocytes and macrophages to 
mycobacterial products. In synergy with IFNγ, TNFα activates macrophages to produce nitric 
oxide synthase 2 (NOS2), allowing infected macrophages to eliminate intracellular bacteria 
(Flesch et al, 1994). Indeed, TNFα and TNFR knockout mice are characterized by higher 
susceptibility to M. tuberculosis and impaired granuloma formation (Bean et al, 1999; Flynn 
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et al, 1995a). Furthermore, human patients receiving inhibitors of TNFα are more susceptible 
to develop TB (Keane et al, 2001). Also IL1β, a central pro-inflammatory molecule, has been 
associated with an effective immune reaction to invading M. tuberculosis. Mice that lack both 
IL1β and α develop larger granulomas and show impaired bacterial clearance when compared 
to wildtype animals (Yamada et al, 2000). Consistently, IL1R knockout mice are 
characterized by impaired survival and succumb to exaggerated mycobacterial growth 
(Juffermans et al, 2000). Immunologic control of M. tuberculosis infection relies on a Type 1 
T-cell response. IL12 is strongly induced following phagocytosis of tubercle bacilli by 
macrophages and DCs and skews the response to a T-helper (TH) 1 IFNγ producing 
phenotype (Ladel et al, 1997). IL12 is so important for the immune response against M. 
tuberculosis, that its exogenous administration to mice can improve survival after bacterial 
challenge (Flynn et al, 1995b). Accordingly, IL12-/- mice and humans with mutations of the 
IL12 system are more susceptible to mycobacterial infection (Cooper et al, 1997; Ottenhoff et 
al, 1998). As mentioned previously, IFNγ is a central cytokine for macrophage activation and 
the control of M. tuberculosis infection. The strongest line of evidence supporting this is 
provided by IFNγ knockout mice that are the most susceptible mouse strain to virulent M. 
tuberculosis (Cooper et al, 1993; Flynn et al, 1993). Moreover, individuals defective in genes 
for IFNγ or its receptor succumb easier to mycobacterial infection (Ottenhoff et al, 1998). 
 
 Not only macrophages and DCs, but also other innate immune cells play an important 
role during the defense response of the host to M. tuberculosis. Natural killer (NK) cells are 
granular lymphocytes of the innate system (Moretta et al, 2008). Human NK cells express 
granulysin a peptide that has been shown to kill M. tuberculosis (Stenger et al, 1999). Human 
NK cells not only lyse infected cells but also actively restrict mycobacterial propagation in an 
apoptosis-dependent but Fas/FasL-independent manner (Brill et al, 2001). In-vivo infections 
have shown that NK cells accumulate two weeks after challenge with M. tuberculosis in the 
lungs of mice and secrete IFNγ, and that NK cell depletion prior and during infection does 
not affect control of mycobacterial growth (Junqueira-Kipnis et al, 2003). This result implies 
that even though NK cells are able to respond to pathogenic mycobacterial challenge, their 
functions must overlap with other immune cells. Neutrophils constitute the first line of 
defense of the innate immune system, phagocytosing and killing pathogens through oxygen-
dependent and/or independent mechanisms, and neutrophil extracellular trap (NET) 
formation (Brinkmann et al, 2004; Segal, 2005; Urban et al, 2009; Urban et al, 2006). For a 
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long time the role of neutrophils during M. tuberculosis infection was neglected. During the 
last years evidence has accumulated suggesting that neutrophils have a function during the 
acute phase of infection and early granuloma formation (Barrios-Payan et al, 2006; Pedrosa et 
al, 2000; Seiler et al, 2003). More recently, two strains of the M. tuberculosis complex of 
varying virulence, M. tuberculosis H37Rv and M. canettii, were shown to induce subcellular 
changes leading to NET formation that captured mycobacteria but were unable to kill them 
(Ramos-Kichik et al, 2009). Despite all these information, the role of neutrophils during 
mycobacterial infection remains controversial. An important open question here is whether 
neutrophils control the spread of the pathogen by killing M. tuberculosis or if they rather 
contribute to development of the pathology.  
 
 Despite all this accumulating knowledge about cellular mechanisms and molecules 
imperative for innate immunity against M. tuberculosis, a person dying every 20 seconds of 
TB still reminds us how limited our understanding of this devastating disease is (World 
Health Organization., 2009). Better innovative treatments will be only possible if we get to 
know more about the basic biology of this devastating disease (Kaufmann, 2006). 
 
 
1.5 Aims of this study 
Since their discovery in the early 90´s miRNAs have revolutionized our 
understanding of gene activity regulation (Bartel, 2004; Lee et al, 1993; Wightman et al, 
1993). Their significant role in the control of gene expression has been described in many 
different biological processes including development of the immune system and orchestration 
of anti-pathogenic responses (Taganov et al, 2007). Despite the crucial relevance of miRNAs 
in the interplay between host and pathogen currently nothing is known about the role of 
miRNAs during the immune response to M. tuberculosis. This doctoral thesis aimed at 
gaining an insight into the immunoregulatory function of miRNAs during mycobacterial 
infection. To this end, the following objectives were pursued: 
 
- Generation of a miRNA expression profile of THP1 cells infected with mycobacterial 
strains of varying virulence. Identification and validation of differentially regulated 
miRNAs. 
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- Identification of miRNAs with pro- or anti-apoptotic properties using an experimental 
ex-vivo model of DR-mediated apoptosis.   
 
- Characterization of the exact molecular mechanisms responsible for pro- or anti-
apoptotic miRNA-mediated phenotypes. Identification of miRNA target genes using a 
combined approach (i.e. microarray expression analysis, pSILAC and ex-vivo 
targeting assays) to detect expression changes at both the transcriptional and 
translational levels.  
 
- Dissection of the mechanisms controlling the expression of pro- or anti-apoptotic 
miRNAs. Assessment of their involvement in the regulation of innate immune 
responses. 
 
- Construction of lentiviral miRNA over-expression constructs for the generation of 
stably transduced macrophages. Characterization of the effects of miRNA over-
expression on the innate immune response to M. tuberculosis 
 
Taken together, this study shall contribute to a better understanding of the innate 
immune response mounted by macrophages infected with mycobacterial pathogens and the 
regulation of this process by miRNAs.  
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2. Material & Methods 
2.1 Material 
2.1.1 Biochemicals and molecular biological reagents 
Name Supplier 
 
1 kb plus ladder 
 
Invitrogen (Carlsbad, CA, USA) 
13C6 15N4 L-Arginine-2HCl Perbio Science (Erembodegem, Belgium) 
13C6 L-Arginine-HCl Perbio Science (Erembodegem, Belgium) 
13C6, 15N2 L-Lysine-2HCl Perbio Science (Erembodegem, Belgium) 
7-Amino-actinomycin (7-AAD) Immunochemistry Technologies (Bloomington, MN, USA) 
AccuPrime Taq Polymerase High Fidelity Invitrogen (Carlsbad, CA, USA) 
Acrylamide/Bis-Acrylamide Bio-Rad Laboratories (Hercules, CA, USA) 
Agarose LE Biozym (Oldendorf, Germany) 
Anti-Fas (Clone CH11) Upstate (Temecula, CA, USA) 
Anti-miRNAs Ambion (Austin, TX, USA) 
Cyclohexamide Sigma Aldrich (St. Louis, MO, USA) 
FastSYBR® Green master mix Applied Biosystems (Carlsbad, CA, USA) 
FLICA® CASP3 Immunochemistry Technologies (Bloomington, MN, USA) 
FLICA® CASP8 Immunochemistry Technologies (Bloomington, MN, USA) 
Glycogen Ambion (Austin, TX, USA) 
Lipofectamine 2000® Invitrogen (Carlsbad, CA, USA) 
L-Lysine-4,4,5,5-d4 hydrochloride Perbio Science (Erembodegem, Belgium) 
Negative ctrl. miRNA and anti-miRNA #1 Ambion (Austin, TX, USA) 
Osteoprotegerin-Fc Biomol (Hamburg, Germany) 
PageRuler® Plus Prestained Protein Ladder Fermentas (Burlington, Canada) 
PMA (phorbol-12-myristate-13-acetate) Cell Signaling (Danvers, MA, USA) 
Pre-miRNAs Ambion (Austin, TX, USA) 
Propidium iodide Immunochemistry Technologies (Bloomington, MN, USA) 
Random hexamers Fermentas (Burlington, Canada) 
SILAC MEM PRO *LYS (D-MEM) KIT Invitrogen (Carlsbad, CA, USA) 
Staurosporine Sigma Aldrich (St. Louis, MO, USA) 
SuperKiller® TRAIL Alexis Biochemicals (Farmingdale, NY, USA) 
SuperSignal West Pico Chemiluminescent 
Substrate 
Pierce (Rockford, IL, USA) 
TNFα Active Bioscience (Hamburg, Germany) 
TOPO Cloning kit Invitrogen (Carlsbad, CA, USA) 
Trizol Invitrogen (Carlsbad, CA, USA) 
Z-VAD-FMK BD-Biosciences (San Jose, CA, USA) 
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2.1.2 Antibodies 
Table 5. Antibodies used for Western blot analysis of protein expression  
Specificity Host species Clone Dilution Supplier 
Anti-mouse IgG HRP-linked goat polyclonal 1:3000 Cell Signaling (Danvers, MA, USA) 
Anti-rabbit IgG HRP-linked goat polyclonal 1:3000 Cell Signaling (Danvers, MA, USA) 
cFLIP Rabbit polyclonal 1:1000 Cell Signaling (Danvers, MA, USA) 
FAIM-s Rabbit polyclonal 1:5000 AntibodyBcn (Barcelona, Spain) 
FASN Rabbit polyclonal 1:1000 Cell Signaling (Danvers, MA, USA) 
GAPDH Rabbit 14C10 1:1000 Cell Signaling (Danvers, MA, USA) 
GSTP1 Mouse 3F2 1:1000 Cell Signaling (Danvers, MA, USA) 
PARP Rabbit polyclonal 1:1000 Cell Signaling (Danvers, MA, USA) 
 
2.1.3 Primers for 3´-UTR cloning 
 Following primers were used for generation of luciferase reporter constructs for 
detecting miRNA-mediated silencing. The amplified fragments encode the full length 3´-
UTR of the candidate target genes. For cloning purposes the XhoI and NotI restriction 
sequences were added to the forward (fw) and reverse (re) primer respectively. 
 
Table 6. Primers used for generation of 3´-UTR luciferase reporter constructs  
Primer Name Primer sequence 5´ 3´ 
FAIM-3´-UTR _fw ctcgag1 TGAATTTTCATCTTAAGAAGTAAAGATCAG 
FAIM-3´-UTR _re gcggccgc2 AAAAGTATTTATTATAGTAAAGGTTACTGTTGT 
FASN-3´-UTR _fw ctcgag CTGCCACCGGAGGTCACT 
FASN-3´-UTR _re gcggccgc GGGAGGCTGAGAGCAGCA 
FASN-from_cds _fw ctcgag GCCCAGGTGGAGGACG 
FASN-from_cds _re gcggccgc ATCTCTCAAGACCACGGCC 
GSTP1-3´-UTR _fw ctcgag AGTGAGGGTTGGGGGGA 
GSTP1-3´-UTR _re gcggccgc AGCTCTCTTAGAAATTTTATTGGTCct 
OPG-3´-UTR _fw ctcgag CTGGAAATGGCCATTGAGC 
OPG-3´-UTR _re gcggccgc AAGGTACATTCAATTTCTCAGAGCA 
1 XhoI restriction sequence 
2 NotI restriction sequence 
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2.1.4 Primers for gene expression quantification 
 Expression levels of osteoprotegerin (OPG), Fas-apoptosis inhibitory molecule 
(FAIM), fatty acid synthase (FASN), glutathione S-transferase pi 1 (GSTP1) were 
determined using commercially available mRNA specific Quantitect primer assays (Qiagen, 
Hilden, Germany). For quantification of interleukin 6 (IL6), 8 (IL8) and human acidic 
ribosomal protein (HuPO) the primers listed below were used. Oligonucleotides were 
designed to span across exons and specifically amplify mRNA transcripts. They were 
purchased from MWG Biotech (Ebersberg, Germany).  
 
Table 7. Detection primers for quantification of gene expression 
Primer Name Primer sequence 5´ 3´ 
HuPO_fw GCTTCCTGGAGGGTGTCC 
HuPO_re GGACTCGTTTGTACCCGTTG 
IL6_fw CAATCTGGATTCAATGAGGAGAC 
IL6_re CTCTGGCTTGTTCCTCACTACTC 
IL8_fw GAACTGAGAGTGATTGAGAGTGGA 
IL8_re CTCTTCAAAAACTTCTCCACAACC 
 
2.1.5 Plasmids 
 Following plasmids were used for the experiments presented here. All luciferase 
expressing plasmids were generated from Promega (Madison, WI, USA). pCR2.1-TOPO® 
was obtained from Invitrogen (Carlsbad, CA, USA). pGL3.ELAM.tk was a kind gift Dr. 
Juana de Diego (Max-Planck Institute for Infection Biology, Berlin, Germany). 
Table 8. Plasmids 
Name Description 
pCR2.1-TOPO® Linearized vector with single 3´thymidine (T) overhangs for TA cloning and Topoisomerase I covalently bound to the vector 
pGL3.ELAM.tk Encodes a luciferase cloned from Photinus pyralis and driven by an NF-κB-responsive element from the E-selectin gene 
pGL3-control Encodes a luciferase cloned from Photinus pyralis and expressed under the control of SV40 early enhancer/promoter region (Yang et al, 1998) 
pRL-SV40 Encodes a luciferase cloned from Renilla reniformis and expressed under the control of SV40 early enhancer/promoter region 
psiCHECK-2 Expresses two luciferases cloned from Renilla reniformis (SV40 early enhancer/promoter) and Photinus pyralis (HSV-TK promoter) 
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2.1.6 Toll-like receptor (TLR) ligands  
 For stimulation of TLRs the human TLR1-9 agonist kit from Invivogen (San Diego, 
CA, USA) was purchased. Lyophilized material was resuspended using endotoxin-free water 
according to the manufacturer´s instructions. Dissolved reagents were aliquoted and stored at 
-80°C.  
 
 
2.1.7 Mycobacterial strains and culture  
 Infection experiments of human macrophages were performed under BL3 conditions 
with the virulent Mycobacterium tuberculosis H37Rv (M. tuberculosis H37Rv) lab strain 
obtained from American Type Culture Collection (Manassas, VA, USA). Recombinant eGFP 
expressing Mycobacterium bovis BCG (M. bovis BCG) was kindly provided by Dr. Nathalie 
Winter from mycobacterial genetics unit (Institute Pasteur, Paris, France). Bacterial cultures 
were grown in Middlebrook 7H9 broth (see 2.1.8). 
 
 
2.1.8 Eukaryotic cell lines 
HeLa and THP-1 cells were obtained from the German Collection of Microorganisms 
& Cell Cultures (DSMZ) (Braunschweig, Germany) and the American Type Culture 
Collection (ATCC) (Manassas, VA, USA), respectively. HeLa and THP-1 cells were 
cultivated in DMEM and complete RPMI (see 2.1.8) at 37°C and 5% CO2 in a humidified 
incubator. After 15 passages cells were discarded and replaced by a new cryostocks. 
 
 
2.1.9 Buffers, solutions and culture media 
Middlebrook 7H9 broth: 4.7 g DifcoTM Middlebrook 7H9 powder 
 2 ml Glycerol 
 900 ml ddH2O 
 100 ml BBL Middlebrook 
 10% (v/v) ADC enrichment 
 0.05% (v/v) Tween 80 
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DMEM for HeLa cells: DMEM 
 10%(v/v) heat-inactivated fetal bovine serum 
 2 mM L-Glutamine 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 sterile filtered 
 
pSILAC DMEM “light”: SILAC DMEM 
 10%(v/v) dialyzed heat-inactivated fetal bovine serum 
 2 mM L-Glutamine 
 2 mM L-Arginine 
 2 mM L-Lysine 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 sterile filtered 
 
pSILAC DMEM “med.-heavy”: SILAC DMEM 
 10%(v/v) dialyzed heat-inactivated fetal bovine serum 
 2 mM L-Glutamine 
 2 mM 13C6 L-Arginine-HCl 
 2 mM L-Lysine-4,4,5,5-d4 hydrochloride 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 sterile filtered 
 
pSILAC DMEM “heavy”: SILAC DMEM 
 10%(v/v) dialyzed heat-inactivated fetal bovine serum 
 2 mM L-Glutamine 
 2 mM 13C6 15N4 L-Arginine-2HCl 
 2 mM 13C6, 15N2 L-Lysine-2HCl 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 sterile filtered 
 
Complete RPMI: RPMI 
 10% heat-inactivated fetal bovine serum 
 2 mM L-Glutamine 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 55 µM 2-mercaptoethanol 
 100 mM Hepes 
 1mM sodium pyruvate 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
 sterile filtered 
 
FLICA washing buffer: 1% BSA (w/v) 
 in PBS 
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MTT solution: 5 mg/mL MTT 
 in PBS 
 
1× PAGE running buffer: 25 mM Tris Base 
 192 mM Glycine 
 0,1 % (w/v) SDS 
 pH ~ 8,5 
 
3×Laemmli buffer: 52,8 mM Tris-HCl, pH 6,8 
 6 % (w/v) SDS 
 30 % (v/v) Glycerol 
 15 % (v/v) β-mercaptoethanol 
 0,024 % (w/v) Bromphenol blue 
 
5 % stacking gel: 125 mM Tris-HCl, pH 6,8 
 5 % (w/v) Acrylamide/Bis-Acrylamide (37,5:1) 
 0,1 % (w/v) SDS 
 0,25 % (v/v) TEMED 
 0,1 % (w/v) APS 
 
10 % SDS resolving gel : 375 mM Tris-HCl, pH 8,8 
 10 % (w/v) Acrylamide/Bis-Acrylamide (37,5:1) 
 0,1 % (w/v) SDS 
 0,15 % (v/v) TEMED 
 0,05 % (w/v) APS 
 
1×Western blot buffer: 25 mM Tris base 
 192 mM Glycine 
 10 % (v/v) Methanol 
 pH ~ 8,5 
 
Stripping buffer: 25 mM glycine 
 1 % (w/v) SDS 
 pH 2,0 
 
1x oligo annealing buffer: 10 mM Tris-HCl (pH 7.5) 
 100 mM NaCl 
 1 mM EDTA 
 
1×TAE: 40 mM Tris base 
 20 mM glacial acetic acid 
 1 mM EDTA 
 
1×TBS: 25 mM Tris-HCl 
 123 mM Sodium chloride 
 5 mM Potassium chloride 
 0,7 mM Calcium chloride-2·H2O 
 0,5 mM Magnesium chloride-6·H2O 
 0,6 mM Di sodium hydrogenphosphate-2·H2O 
 pH 7,4 
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1×TBS/T: 1×TBS 
 0,1 % (v/v) Tween-20 
 
 
2.2  Methods 
2.2.1 Infection of THP-1 macrophages 
 Infection experiments were performed in 6-well plates. In order to induce cell 
adherence and differentiation 106 THP-1 suspension cells per well were stimulated overnight 
in culture medium (see 2.1.7) with 50 ng/ml PMA. Following stimulation, cell culture 
supernatant was discarded and adherent cells were rinsed five times with fresh medium in 
order to remove any remaining PMA traces. Subsequently two milliliters of medium were 
added to the cells and these were kept in culture for another 24 hrs. After this time, cell 
monolayers were washed once more with culture medium and then cultured for two more 
days in order to allow the cells to fully differentiate into macrophage-like cells. Second or 
third passage bacterial cultures in the exponential growth phase (OD600 = 0,7) were used for 
infection. The inoculum was prepared by sedimenting mycobacterial cultures via 
centrifugation at 3000 rpm for 10 min and washing them once with 10 ml PBS in order to 
dilute any remaining culture broth. Resuspended bacteria were sedimented again and then 
resuspended in 3 ml PBS. In order to avoid clump formation, the bacterial suspension was 
passed ten times through a 25 gauge needle and finally filtered using 40µm cell filters from 
BD-Biosciences (San Jose, CA, USA). Cells were infected in complete culture medium 
without antibiotics with a final multiplicity of infection (MOI) of 20:1 or 3:1 with M. bovis 
BCG or M. tuberculosis H37Rv, respectively. After inoculation, the culture plates were 
centrifuged 5 min at 1500 rpm in order to sediment the mycobacteria and facilitate 
phagocytosis. Infected cells were cultured four hours after which the supernatant was 
removed and cells were washed three times with complete medium without antibiotics. After 
the last washing step fresh medium was added and cells were incubated for another 24 or 48 
hrs. at 37°C and 5% CO2 in a humidified incubator. 
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2.2.2 Transient transfection 
 Transient transfection of HeLa cells was performed in 24-well format using Optimem 
serum-free medium and Lipofectamine2000® both from Invitrogen (Carlsbad, CA, USA). 
The day prior to the experiment 5*104 cells were seeded per well. Transfection of the cells 
was performed as per manufacturer´s recommendations. 
 
 
2.2.3 Bacterial transformation 
 One Shot® TOP10 chemically competent E. coli from Invitrogen (Carlsbad, CA, 
USA) were transformed according to manufacturer’s instructions. Cryostocks were generated 
by storing transformed cells in LB with 7.5% Glycerol at -80°C. 
 
 
2.2.4 Microarray analysis 
Microarray experiments were performed as dual-color hybridizations. To compensate 
for dye-specific effects, a dye-reversal color-swap was applied (Churchill, 2002). Quality 
control and quantification of total RNA amount was assessed using an Agilent 2100 
bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and a NanoDrop 1000 
spectrophotometer (Kisker, Steinfurt, Germany). RNA labeling was performed with the 
Quick Amp Labeling Kit (Agilent Technologies). In brief, mRNA was reverse transcribed 
and amplified using an oligo-dT-T7-promotor primer. The obtained resulting cRNA was 
labeled with either Cyanine 3-CTP or Cyanine 5-CTP. After precipitation, purification and 
quantification, 1.25 µg of each labeled cRNA was fragmented and subsequently hybridized to 
whole human genome 44k microarrays (AMADID-014850) according to the supplier’s 
protocol (Agilent Technologies). Hybridized microarrays were washed using the SSC 
washing protocol (Agilent Technologies). Scanning of microarrays was performed with 5 µm 
resolution using a DNA microarray laser scanner (Agilent Technologies). Raw microarray 
image data were analyzed with the Image Analysis / Feature Extraction software G2567AA 
(Version A.9.5.1, Agilent). The extracted MAGE-ML files were further analyzed with the 
Rosetta Resolver Biosoftware, Build 7.2 (Rosetta Biosoftware, Seattle, WA, USA). Ratio 
profiles comprising single hybridizations were combined in an error-weighted fashion to 
create ratio experiments. A 1.5 fold-change expression cut-off for ratio experiments was 
applied together with anti-correlation of ratio profiles. 
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2.2.5 Sample preparation for pSILAC analysis 
Changes in the proteome of miRNA-133b transfected HeLa cells were analyzed by 
performing a slightly modified version of the method described by Selbach et. al (Selbach et 
al, 2008) in cooperation with Dr. Bernd Thiede from the Biotechnology Centre of the 
University of Oslo (Oslo, Norway). Briefly, HeLa cells were cultivated during 5 passages in 
“light” culture medium (see 2.1.8) in order to ensure a complete labeling of the proteins with 
amino acids marked with light isotopes. “Light”-labeled cells were transfected for 8 hours 
with the 5 pmol control miRNA (ctrl. miRNA) or miRNA-133b. Subsequently, cells were 
transferred to culture medium containing medium-heavy or heavy isotope-labeled amino 
acids and pulse labeled for another 40 hours. After this time, both groups of cells were 
stimulated in the same media with 20 ng/ml TNFα for 6 hrs. Finally, stimulated labeled cells 
were collected by trypsination and sent out to our cooperation partners in Oslo for 
downstream mass spectrometry quantification of protein levels.  
 
 
2.2.6 Molecular biological methods 
2.2.6.1 Cloning of 3´-UTR luciferase reporter constructs 
Validation of miRNA-targets with canonical miRNA binding sites was performed by 
cloning the complete 3’UTR of the predicted genes. To this end 3´-UTRs were amplified by 
polymerase chain reaction (PCR) using AccuPrime Taq Polymerase High Fidelity and 
primers designed to have restriction sites for XhoI and NotI (see 2.1.3, Table 3) PCR 
products were subcloned into pCR2.1-TOPO (Invitrogen) and subsequently cloned into 
XhoI/NotI digested psiCHECK-2 plasmid from (Promega). This vector enables monitoring of 
changes in expression of a target 3´-UTR fused to a reporter gene. It uses Renilla luciferase 
as primary reporter gene, and the 3´-UTR of interest is cloned into a multiple cloning region 
located downstream of the Renilla translational stop codon. Initiation of the RNAi process by 
synthetic miRNA or in vivo-expressed miRNAs results in down-regulation of the fusion 
mRNA. PsiCHECK-2 also contains a second reporter gene, Photynus (firefly) luciferase, 
which allows normalization of Renilla luciferase expression thus compensating for 
differences of the transfection efficiency of different samples (Scheme 9). 
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Scheme 9. Action mechanism of psiCHECK-2 3´UTR luciferase reporter constructs for miRNA target 
 
 
2.2.6.2 Generation of 5´-UTR luciferase reporter constructs 
 Validation of potential binding sites in the 5´-UTR of OPG was performed by 
inserting either the complete 5´-UTR or the predicted miRNA-133b binding sequence only. 
Amplification of the 5´-UTR was performed by polymerase chain reaction (PCR) using 
AccuPrime Taq Polymerase High Fidelity and primers designed to have restriction sites for 
HindIII and NcoI (fw-primer AAGCTTTTTTTTTCCCCTGCTCTCC ; re-primer 
CCATGGTGTGGTCCCCGGAAACC). The PCR product was subcloned into pCR2.1-
TOPO (Invitrogen) and subsequently inserted into HindIII/NcoI digested pGL3-ctrl plasmid 
(Promega) (Scheme 10). To generate a luciferase reporter plasmid containing only the in-
silico predicted miRNA-133b binding sequence in the 5´-UTR of OPG, 5´-phosphorylated 
DNA oligos (MWG) corresponding to this sequence and harboring HindIII and NcoI 
restriction sites (fw-oligo P-AGCTAAGCCCCTGAGGTTTCCGGGGACCACT; re-oligo P-
CATGAGTGGTCCCCGGAAACCTCAGGGGCTT) were annealed and ligated into 
HindIII/NcoI digested pGL3-ctrl plasmid. Oligo annealing was performed by dilution of 
equal molar amounts of both fw- and re-oligo in 1x oligo annealing buffer and heating this 
solution at 95°C for 5 min. Finally, the solution was allowed to cool slowly to room 
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temperature (RT) by unplugging the power supply of the heating block. Annealed oligos were 
stored at -20°C. 
 
 
Scheme 10. Cloning strategy for generating 5´-UTR miRNA-targeting reporter constructs using pGL3-ctrl 
 
 
2.2.6.3 RNA isolation and cDNA synthesis 
Total RNA for quantitative PCR and Microarray analysis was isolated with TRIzol 
(Invitrogen, Carlsbad, CA, USA) according to the total RNA-isolation protocol 
recommended by the manufacturer and using glycogen (Ambion, Austin, TX, USA) as a 
carrier for precipitation of nucleic acids. 2 µg total RNA per sample were transcribed to 
cDNA with random hexamer primers (Fermentas, Burlington, Canada) and SuperScript® II 
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) as per manufacturer´s instructions. 
After reverse transcription all samples were subjected to DNAseI (Invitrogen) treatment in 
order to remove contaminating genomic DNA. 
 
 
2.2.6.4 Semi-quantitative real-time PCR 
Analysis of gene expression was performed using gene-specific primers specifically 
designed to bind and amplify only mRNA sequences (see 2.1.4). Amplification and detection 
reactions were done using FasSYBR® Green master mix from Applied Biosystems 
(Carlsbad, CA, USA). Briefly, 4 µl diluted cDNA (1 to 50 aqueous dilution, see 2.2.7.1), 1.2 
µl 1:1 primer mix (1.25 µM each) were added to 5 µl FastSYBR® Green master mix per 
well. Samples were measured in triplicates using a 7900HT fast real-time PCR system 
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(Applied Biosystems) set to perform the “fast” amplification protocol. Fold-changes in gene 
expression were calculated using the comparative ΔΔCt method and taking human acidic 
ribosomal protein (HuPO) as an internal standard (Bookout et al, 2006).  
 
 
2.2.6.5 miRNA quantification 
Quantitative PCR of miRNA was performed with TaqMan® miRNA assays from 
Applied Biosystems using 100 ng total RNA for the reverse transcription step. All samples 
were diluted 1 to 7.5 with ddH2O and analyzed with a 7900HT fast real-time PCR system 
(Applied Biosystems). Fold-changes in gene expression were calculated using the 
comparative ΔΔCt method and RNA-U6B small nuclear (RNU6B) as internal standard 
(Bookout et al, 2006).  
 
 
2.2.7 Biochemical methods 
2.2.7.1 SDS-PAGE and Western blotting.  
Protein lysates were generated by harvesting 5*105 cells previously transfected and/or 
stimulated with apoptotic stimuli (see 2.2.8) in 100 µl 1x Laemmli sample buffer (Laemmli, 
1970). 10-20 µl per lane of cell lysates were separated by SDS-PAGE. Tris-Glycine buffered 
SDS-polyacrylamide gels with 5% stacking gel and 12% resolving gel were used. Gels were 
run in 1x PAGE buffer at 100V for 60-90 min. Following SDS-PAGE proteins were 
transferred to PVDF membrane (Millipore, Billerica, MA, USA) using a semi dry 
electroblotting protocol. This was performed using a bloting machine and 1x Western blot 
buffer. Protein transfer took place at 1 mA/cm2 for two hours. Following transfer the 
membrane was rinsed with TBS/T and blocked for one hour at RT in TBS/T containing 5% 
(v/v) non fat dry milk. The membrane was incubated overnight at 4°C on an orbital incubator 
with the primary antibody diluted in TBS/T containing 3% (v/v) non fat dry milk (see 2.1.2 
Table 2). Next day, the antibody solution was removed and the membrane was rinsed at RT 
four times 15 min with fresh TBS/T. Horseradish peroxidase (HRP) -coupled secondary 
antibodies diluted in TBS/T (see 2.1.2 Table 2) was added to the membrane for one hour at 
RT under constant shaking. Following incubation, the membrane was washed three times 10 
min. with fresh TBS/T. Enhanced chemoluminescence (ECL) reaction was performed using 
the SuperSignal West Pico Chemiluminescent Substrate (Pierce) according to the 
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manufacturer´s instructions. Membranes were analyzed using LAS-3000 CCD imaging 
system from Fujifilm (Tokyo, Japan). Band intensity was quantified densitometrically using 
the AIDA Biopackage -2D (Raytest, Straubenhardt, Germany).  
 
 
2.2.7.2 OPG ELISA.  
Levels of secreted OPG were determined in the supernatant of transfected cells with 
the human Osteoprotegerin DuoSet from R&D Systems (Minneapolis, MN, USA) according 
to the manufacturer’s indications. To this end HeLa cells were seeded in 96-well plates, 
transfected with 5 pmol miRNA or/and 15 pmol antimiRNA (αmiRNA) and incubated for 48 
or 72 hours in 300 µl culture medium before collection of the supernatants. At the specified 
time points 250 µl supernatants were collected and either used immediately for the 
determination of secreted OPG or stored at -80°C. All samples were analyzed in triplicates 
using a Spectramax 190 reader from Molecular Devices (Sunnyvale, CA, USA). Values were 
normalized to total number of metabolically active cells per well as determined by MTT-
assay performed with the same culture plates (see 2.2.5.3).  
 
 
2.2.7.3 MTT-Assay 
 A 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell survival 
and proliferation assay was used for normalizing the amount of secreted OPG, as determined 
by ELISA (see 2.2.5.2), to the total number of living cells per well (Mosmann, 1983). Briefly, 
MTT was diluted in PBS to a final concentration of 5 mg/ml, sterile filtered and stored away 
until use at -20°C. At the specified time points, MTT stock solution was further diluted with 
DMEM medium (w/o FCS) to a final concentration of 100 µg/ml. To perform the assay 50 µl 
of this solution were added to the culture plate containing the transfected cells in 50 µl 
supernatant (see 2.2.5.2). Treated cells were incubated for another 5 hours at 37°C and 
controlled hourly with a light microscope for the formation and precipitation of violet 
formazan crystals. Next, cell culture supernatants were removed carefully, taking care not to 
disturb the cell monolayer, and adherent cells were lysed with 100 µl DMSO. Finally, DMSO 
samples containing the diluted formazan crystals were transferred to ELISA plates and the 
OD570 values were determined by using a Spectramax 190 reader from Molecular Devices. 
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2.2.7.4 NF-κB activity luciferase assay 
 For determining NF-κB activity HeLa cells were co-transfected with 30 pmol miRNA 
and/or 90 pmol αmiRNA, 100 ng pGL3.ELAM.tk and 10 ng pRL-SV40 (see 2.2.2). 
Transfected cells were incubated for 48 hrs. before they were either left untreated or primed 
for 4 hrs. with 20 ng/ml TNFα or 10 µg/ml poly(I:C). Luciferase activity was measured using 
the Dual-Luciferase® Reporter Assay System from Promega (Madison, WI, USA) as per 
manufacturer´s recommendations. Briefly, transfected stimulated cells were washed once 
with PBS and lysed with 200 µl of 1x passive lysis buffer (PLB). Cell lysates were incubated 
on an orbital plate shaker at 200 rpm for 15 min. in order to assure complete lysis of the cells. 
Next, samples were diluted 1 to 10 using PLB. Luciferase assays were performed in 
triplicates in white 96-well plates using 15 µl lysate and 35 µl of both substrates for the 
Photynus and Renilla luciferases per well. Measurement of light emission was performed on 
Victor luminometer (Perkin Elmer, Waltham, MA, USA). Cells transfected with ctrl. miRNA 
were used as reference point for each different type of treatment.  
 
 
2.2.7.5 miRNA-targeting luciferase assay 
Luciferase reporter assays were performed by co-transfecting HeLa cells with 100 ng 
psiCHECK-2 3´-UTR or pGL3-ctrl 5´-UTR constructs and 5 pmol ctrl. miRNA or miRNA-
133b. For blocking experiments 15 pmol ctrl. αmiRNA or αmiRNA-133b were included. In 
5´-UTR targeting experiments pRL-SV40 was included as normalization control. 48 hours 
post-transfection cells were rinsed once with PBS and lysed with PLB. Cell lysates were 
incubated on an orbital plate shaker at 200 rpm for 15 min. in order to assure complete lysis. 
Next, samples were diluted 1 to 10 using PLB. Dual luciferase assay was performed in 
triplicates on white 96-well plates using 15 µl lysate and 35 µl of both substrates for the 
Photynus and Renilla luciferases per well. Measurement of light emission was performed on 
VICTOR luminometer (Perkin Elmer, Waltham, MA, USA). Total luciferase activity (Renilla 
reniformis) was calculated by normalizing to the firefly (Photinus pyralis) luciferase in order 
to correct for differences in the transfection efficiency. 
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2.2.8 Apoptosis detection  
 Samples for apoptosis quantification were prepared as follows: HeLa cells were 
transfected with 5 pmol ctrl. miRNA or miRNA-133b. For inhibition experiments 15 pmol 
ctrl. αmiRNA or αmiRNA-133b were co-transfected. 48 hours post-transfection cells were 
stimulated with 20 ng/ml TNFα (with or without 10 µg/ml cycloheximide (CHX)), 100 ng/ml 
of a cross-linking activating antiCD95 antibody (αCD95) or 20 ng/ml recombinant human 
TRAIL (rhTRAIL). 1µM staurosporine (STA) was used as a positive control. Chemical 
inhibition of apoptosis was achieved by incubating the cells with 50 µM carbobenzoxy-valyl-
alanyl-aspartyl-[O-methyl]- fluoromethylketone (Z-VAD-FMK) one hour prior to addition of 
DR ligands or chemical apoptosis inducers. Four hours after stimulation cells were assessed 
for the presence of activated caspases, poly (ADP ribose) polymerase (PARP) cleavage, 
genomic fragmentation or loss of membrane integrity.  
 
 
2.2.8.1 Quantification of active CASP8 and 3 
Apoptotic cells were quantified by flow cytometric determination of CASP8 and 3 
activation using fluorescent-labeled inhibitors of caspases (FLICATM) from 
Immunochemistry Technologies (Bloomington, MN, USA). All procedures were done 
according to manufacturer´s instructions.  
 
 
2.2.8.2 TUNEL assay 
Genomic DNA fragmentation was assayed with the ApoDirect® kit from BD-
Biosciences which is a two-color staining method for labeling DNA breaks and total cellular 
DNA to detect apoptotic cells by flow cytometry. Staining of the cells was performed 
according to the instructions delivered by the manufacturer. 
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2.2.8.3 PI-incorporation assay 
Propidium iodide (PI) incorporation was used for determining the overall cell vitality. 
Briefly, trypsinized cells were washed once with warm PBS and resuspended in FLICA 
washing buffer containing 20 µg/ml PI. Cells were incubated for 30 min. at RT protected 
from light before flow cytometry quantification.  
 
 
2.2.9 Statistics 
Unless otherwise specified, data shown is representative for the results of at least 
three independent experiments. Statistical significance was calculated by two-tailed Student’s 
t-test and p<0.05 was considered significant. 
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3. Results 
3.1 miRNA expression profile of mycobacterial infection  
Based on the importance of miRNAs for the mounting and appropriate function of 
innate immune responses, a miRNA expression profile of human macrophages infected with 
M. tuberculosis H37Rv (virulent) or M. bovis BCG (avirulent) was generated. PMA-
differentiated THP-1 cells were infected and incubated for 24 or 48 hrs. At the respective 
time points, total RNA was isolated and analyzed on miRNA expression microarrays. Of the 
534 human miRNAs covered by the scanning platform only nine were differentially regulated 
(fold-change ≤ -1.5 or ≥ 1.5) after infection of macrophages with the mycobacteria (Table 1.). 
 
Table 9. miRNAs differentially expressed in THP1 macrophages after mycobacterial infection 
 
M. bovis BCG 
 
M. tuberculosis H37Rv  Name 
FCH 241 FCH 482 FCH 24 FCH 48 
miRNA-133b 52.5 2.2 n.d3. n.d. 
miRNA-146a 3.4 2.7 n.d. n.d. 
miRNA-155 2.3 2.5 1.5 1.5 G
1 
miRNA-339 (G4) 1.6 -2.4 -2.4 -2.2 
miRNA-137 -7.9 -2.8 n.d. n.d 
miRNA-145 -4 -3.9 n.d n.d. G
2 
miRNA-340 -2 -4.7 n.d. n.d. 
let-7e (G4) -2.1 1.6 -1.7 -2 
G
3 
miRNA-27a (G4) 2.7 -3 -1.6 -2.1 
1 FCH 24 = fold change in miRNA expression after 24 hours infection. 
2 FCH 48 = fold change in miRNA expression after 48 hours infection.  
3 n.d. = not detected  
 
 
According to their expression profile the detected miRNAs could be categorized in 
four different groups. The first group (G1) contained miRNAs showing consistent up-
regulation during the complete time course of the experiment after infection with M. 
tuberculosis H37Rv, M. bovis BCG or in both cases. These included previously well 
characterized immunoregulators like miRNA-146a and -155, but also novel ones such as 
miRNA-133b and -339 (O'Connell et al, 2007; Taganov et al, 2007). The second category 
(G2) of miRNAs included those detected as down-regulated at both time points after 
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infection with M. bovis BCG, such as miRNA-137, -145 and -340. MiRNA-27a and let-7e 
fitted in the third group (G3) and were characterized by a more dynamic expression profile 
and opposite regulation polarities at 24 and 48 hrs. of infection with M. tuberculosis H37Rv 
or M. bovis BCG. Finally, the fourth group (G4) of miRNAs enclosed those displaying 
contradictory expression profiles depending on the time point and whether the cells were 
infected with M. tuberculosis H37Rv or M. bovis BCG. For all miRNAs, except miRNA-137 
the expression profile delivered by the microarray analysis could be corroborated by 
quantitative polymerase-chain-reaction (qPCR) using independent samples. In the case of M. 
tuberculosis H37Rv infection, contrary to the results delivered by the microarray 
experiments, the qPCR analysis revealed a previously undetected differential regulation of 
the miRNAs -133b, -137, -145, 146a and -340 (Figure 1). 
 
 
Figure 1. qPCR validation of miRNA microarray expression profile.  
PMA-differentiated THP-1 cells were infected with M. bovis BCG (upper graph) or M. tuberculosis H37Rv 
(lower graph) and incubated for 24 (black bars) and 48 hrs (white bars). At each time point, total RNA was 
harvested and used for miRNA-specific qPCR analysis. Infection samples were compared to differentiated 
uninfected cells that had been cultivated simultaneously for the same period of time. RNU6B was used as an 
internal standard for normalization. Values were calculated by performing the ΔΔCt-method (Bookout et al, 
2006).  
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In summary, using this platform very strong effects such as up-regulation of miRNA-
133b in M. bovis BCG infected cells, mild effects like those observed for miRNA-339 and 
significant down-regulation of miRNA species such as the one observed for miRNA-145 and 
-137 could be detected. These results indicate that mycobacterial infection of human 
macrophages leads to changes in miRNA expression levels.  
 
 
3.2 miRNA-133b sensitizes resistant cells to TNFα-induced apoptosis 
Next to the identification of miRNAs differentially regulated after infection of human 
macrophages with mycobacteria, their involvement in the regulation of innate immunity was 
characterized. As a special focus the investigation of the role these miRNAs might play in the 
regulation of TNFα-signaling and TNFα-induced apoptosis was chosen. The major 
challenges of working with miRNAs and macrophages are the engineering, transfection and 
over-expression of genetic constructs (Lee & Reiner, 2009; Zhang et al, 2009). Therefore, to 
be able to easily test all candidate miRNAs, a well characterized and easy to transfect HeLa 
cell line model was selected. HeLa cells are TNFα-responsive but, due to strong activation of 
the NF-κB signaling pathway, they do not undergo apoptosis. Several years ago it was 
demonstrated that the pro-apoptotic effect of TNFα could be blocked in a NF-κB dependent 
manner (Beg & Baltimore, 1996; Liu et al, 1996b; Van Antwerp et al, 1996; Wang et al, 
1996). Upon activation, NF-κB is released, translocates to the nucleus and induces the 
expression of anti-apoptotic molecules such as the cIAP1/2, XIAP, (cFLIP), manganese 
superoxide dismutase (MnSOD), TNF-receptor associated factor 1 and 2 (TRAF1/2) and 
several members of the BCL-2 family (Dutta et al, 2006; Shen & Tergaonkar, 2009).  
 
In order to test whether the identified miRNAs play regulatory functions within the 
TNFα-signaling pathway, HeLa cells were transfected with synthetic miRNA precursors that 
mimicked the differentially regulated miRNAs detected during the infection screen. As a 
negative control the cells were transfected with scrambled miRNA (ctrl. miRNA), a molecule 
with no known sequence homology to any human gene. 48 hrs. later the cells were stimulated 
with TNFα and, the activation status of pro-apoptotic CASP8 was measured. Cycloheximide 
(CHX), a potent protein synthesis inhibitor, was added during the stimulation in order to 
block the de-novo synthesis of anti-apoptotic proteins and force the cells to undergo 
programmed cell death. Irrespective of the transfected miRNA, unstimulated cells showed 
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low levels (4 to 8% of the cells) of cleaved CASP8. Four hours after addition of TNFα and 
CHX to the cell culture 40, 35, 28 and 42% of the cells respectively transfected with the 
negative control, miRNA-27a, -146a or -155, stained positive for active CASP8. This 
proportion increased to 75% of the cells after transfection of miRNA-133b, indicating that 
this miRNA might be pro-apoptotic (Figure 2). 
 
 
Figure 2. miRNA-133b enhances CASP8 cleavage in HeLa cells treated with TNFα and CHX.  
Cells were transfected with synthetic miRNA mimics or a negative control (ctrl. miRNA). After incubation for 
48 hrs., cells were either left untreated (left) or stimulated with 20 ng/ml TNFα and 10 µg/ml CHX in order to 
induce apoptosis (right). Four hours after stimulation the percentage of cells displaying the activated form of the 
pro-apoptotic CASP8 was determined by flow cytometry.7-AAD was included as an exclusion marker for cells 
with a leaky plasma membrane(Schmid et al, 1992). Cells transfected with ctrl. miRNA were treated with 
staurosporine (STA), a potent pro-apoptotic substance, as a positive control. Both graphs are representative of at 
least three independent experiments.* symbolizes a p-value smaller than 0.01. Errors bars = standard deviation 
 
Defining apoptosis based on quantification of only one characteristic feature, for 
instance the activation of pro-apoptotic caspases, is insufficient and increases the risk of 
focusing on experimental artifacts (Kroemer et al, 2009). In order to avoid this, the response 
of miRNA-133b transfected cells to TNFα and CHX was further characterized by quantifying 
the degree of genomic DNA fragmentation, a typical feature of apoptotic cells (Wyllie et al, 
1984). First dUTP nick end labeling (TUNEL) assay was performed with cells that had been 
transfected with either the negative control or miRNA-133b and subsequently incubated for 
another 48 hrs (Gavrieli et al, 1992). Both groups of transfected cells showed almost no 
detectable signs (~2% positive cells) of genomic DNA disintegration (Figure 3A). After 
stimulation with TNFα and CHX, 20% of the ctrl. miRNA transfectants stained positive for 
dUTP-FITC. This proportion increased to 54% of the cells in the case of miRNA-133b, 
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representing a 2.7 fold increase with respect to the result observed for cells transfected with 
the negative control (Figure 3B).  
 
 
Figure 3. miRNA-133b transfectants undergo enhanced genomic DNA fragmentation after treatment with 
TNFα and CHX.  
Cells were transfected with a ctrl. miRNA or miRNA-133b mimic and incubated for 48 hrs. After incubation, 
transfected cells were either left untreated (A) or stimulated with 20 ng/ml TNFα and 10 µg/ml CHX in order to 
induce apoptosis (B). Four hours after stimulation all cells were harvested and stained for genomic double 
breaks using the TUNEL assay. STA treated cells served as positive control. Graphs are representative of at 
least three independent experiments. * symbolizes a p-value smaller than 0.01. Errors bars = standard deviation 
 
After observation of increased mortality mediated by miRNA-133b, the next step was 
to characterize its pro-apoptotic potential in the absence of CHX. MiRNA-133b treatment 
sensitized otherwise resistant HeLa cells to TNFα-triggered CASP8 and 3 activation (Figure 
4A). In line with this, poly (ADP ribose) polymerase (PARP) cleavage, another hallmark of 
apoptotic cells, could only be observed in miRNA-133b transfectants (Figure 4B) (Kaufmann 
et al, 1993). Both effects were sequence specific, since transfection of the scrambled negative 
control did not result in an altered activation status of CASP8, 3 or PARP degradation. 
Moreover, both activation of pro-apoptotic caspases and cleavage of PARP could be fully 
restrained by adding a specific miRNA-133b inhibitor (αmiRNA-133b), but not the negative 
control (ctrl. αmiRNA). The basal activation status of CASP8 and 3 in unstimulated 
transfected cells, as well as the amount of cleaved PARP, was slightly elevated in miRNA-
133b transfected samples (Figure 4A and B). Although these effects were small they were 
significant and specific to this miRNA. In summary, these results suggested that miRNA-
133b has a pro-apoptotic nature capable of impairing the pro-survival program characteristic 
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of TNFα-treated cells. Furthermore, this implied a down-regulation of anti-apoptotic 
molecules. 
 
 
Figure 4. TNFα-resistant cells become sensitive after miRNA-133b transfection.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). After 48 hrs. cells were either left untreated or stimulated four 
hours with 20 ng/ml TNFα. A) Treated cells were harvested, stained and scanned by flow cytometry for the 
presence of cleaved active CASP8 (upper graph) and 3 (lower graph). Cells transfected with ctrl. miRNA alone 
were used as a reference. B) Western blot analysis of PARP in transfected, unstimulated (upper panel) and 
TNFα-treated cells (lower panel). GAPDH was used as an internal loading control. Graphs are representative of 
at least three independent experiments. * symbolizes a p-value smaller than 0.01. Errors bars = standard 
deviation 
 
 
3.3 miRNA-133b promotes FasL-triggered apoptosis and leads to exacerbated TRAIL 
responsiveness 
HeLa cells are mostly Fas ligand (FasL) refractory and do not undergo apoptosis upon 
receptor ligation. In a fashion similar to the mechanism responsible for the TNFα-resistance, 
Fas (CD95) stimulation in these cells leads to strong NF-κB activation and de-novo synthesis 
of potent anti-apoptotic molecules (Wajant et al, 2003). To test whether miRNA-133b is 
capable of modifying the cellular response to additional members of the DR ligand family, 
HeLa cells were transfected with miRNA-133b, incubated for 48 hrs. and activated either 
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with a cross-linking antibody against Fas or with recombinant human TRAIL (rhTRAIL). 
After stimulation, the activation status of the cell was assessed by quantification of active 
CASP8, 3 and PARP cleavage. 
 
 
Figure 5. miRNA-133b sensitizes HeLa cells to FasL and TRAIL induced caspase activation.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). After 48 hrs. cells were left untreated or stimulated four hours 
with either 100 ng/ml of a cross-linking activating antiCD95 antibody (αCD95) or 20 ng/ml recombinant human 
TRAIL (rhTRAIL). Treated cells were harvested, stained and scanned by flow cytometry for the presence of 
cleaved active CASP8 (upper graph) and 3 (lower graph). Cells transfected with ctrl. miRNA alone were used as 
a reference. Graphs are representative of at least three independent experiments. * symbolizes a p-value smaller 
than 0.01. Errors bars = standard deviation 
 
Transfection of the cells with miRNA-133b impaired the cellular obstruction of 
caspase activation after Fas stimulation, as reflected by fivefold higher percentage of cells 
harboring the cleaved active form of CASP8 and 3 (compared to the ctrl. miRNA) (Figure 5). 
In line with this, PARP cleavage was only observed in stimulated cells previously transfected 
with the miRNA-133b (Figure 6). TRAIL stimulated cells, were characterized by a strong 
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pro-apoptotic phenotype. Transfection of miRNA-133b enhanced this natural responsiveness 
and led to an exacerbated apoptotic response. After 4 hrs. TRAIL stimulation, 20 and 25% of 
the ctrl. miRNA cells stained positively for CASP8 and 3, respectively. This proportion 
expanded to 46 and 64% in miRNA-133b transfected cells (Figure 5). The increased levels of 
initiator and executor caspases correlated well with an enhanced cleavage of PARP, as 
demonstrated by the almost complete absence of the full-length protein after transfection of 
the cells with miRNA-133b and TRAIL stimulation (Figure 6). In all cases the observed 
effects were sequence specific and could only be fully blocked by co-transfection of a 
specific αmiRNA, but not by an unspecific one. Hence, these results demonstrate that the pro-
apoptotic potential of miRNA-133b was not restricted to TNFα-treatment and that it also 
affected in a specific manner the cellular responses to FasL or TRAIL.  
 
 
Figure 6. miRNA-133b sensitizes HeLa cells to FasL and TRAIL induced PARP cleavage.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). After 48 hrs. cells were stimulated four hours with either 100 
ng/ml of a cross-linking activating antiCD95 antibody (αCD95) or 20 ng/ml recombinant human TRAIL 
(rhTRAIL). After stimulation, cell protein lysates were prepared and the proteolytic cleavage of PARP was 
assessed by Western blot. GAPDH was used as an internal loading control. Blots are representative of at least 
three independent experiments.  
 
 
3.4 Loss of plasma membrane integrity is enhanced by miRNA-133b 
Late apoptotic cells are characterized by compromised plasma membrane integrity 
(Gorczyca, 1999; Patel et al, 2006). To test whether miRNA-133b led to an altered 
permeability status or promiscuous rupture of the cellular envelope after cell death induction, 
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transfected HeLa cells were stimulated with different DR ligands and stained with propidium 
iodide (PI). PI is membrane impermeant and generally excluded from viable cells. It is 
commonly used for identifying cells with impaired membrane integrity. In average 20.3% of 
the unstimulated cells transfected with miRNA-133b were PI-positive, compared to ctrl. 
miRNA transfected cells. Addition of αmiRNA-133b decreased this proportion to 6.4% 
(Figure 7; upper row). This effect of miRNA-133b on the cell membrane permeability 
became more evident after stimulation of the cells with DR ligands, as demonstrated by 
increased PI incorporation. Treatment with TNFα, αCD95 or rhTRAIL resulted in 57, 77 and 
63% PI-positive cells, respectively. Once more, this effect was specific for miRNA-133b, as 
it could be blocked exclusively by a sequence specific inhibitor but not by a negative control 
sequence (Figure 7, lower three rows). 
 
 
Figure 7. miRNA-133b treatment results in enhanced loss of membrane integrity.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). After 48 hrs. cells were left untreated or stimulated four hours 
with either 20 ng/ml TNFα, 100 ng/ml of a cross-linking activating antiCD95 antibody (αCD95) or 20 ng/ml 
recombinant human TRAIL (rhTRAIL). Following stimulation both adherent and suspension cells were 
collected, stained with propidium iodide (PI) and analyzed by flow cytometry. Samples were compared to 
equally treated ctrl. miRNA transfected cells (black histogram). Results are representative for at least three 
independent experiments.  
 
Caspases are a group of cysteine proteases critical for apoptosis of eukarytic cells 
(Wang & Lenardo, 2000). To confirm the apoptotic nature of the miRNA-133b effect on the 
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enhanced loss of membrane integrity, transfected HeLa cells were stimulated with DR 
ligands both in the absence or presence of carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- 
fluoromethylketone (Z-VAD-FMK), a cell-permeable inhibitor that irreversibly binds to the 
catalytic site of caspases thus inhibiting the induction of apoptosis. Addition of Z-VAD-FMK 
to both un- and stimulated miRNA-133b transfected cells was characterized by a strongly 
reduced population of PI-incorporating cells, when compared to equally stimulated cells 
treated with the inhibitor solubilizing agent (Figure 8). Hence, miRNA-133b treatment of 
HeLa cells led to increased loss of membrane integrity in a caspase-dependent manner. This 
suggested that miRNA-133b as pro-apoptotic molecule is capable of impairing the 
mechanisms responsible for keeping an intact cellular envelope.  
 
 
Figure 8. Loss of membrane integrity mediated by miRNA-133b is caspase dependent.  
Cells were transfected either with a control miRNA or miRNA-133b. 48 hrs. after transfection cells were left 
untreated or stimulated four hours with either 20 ng/ml TNFα, 100 ng/ml of a cross-linking activating antiCD95 
antibody (αCD95) or 20 ng/ml recombinant human TRAIL (rhTRAIL). Z-VAD-FMK (50 µM) or 0.01% 
DMSO (vehicle) were added simultaneously to the cells. After stimulation both adherent and suspension cells 
were collected, stained with propidium iodide (PI) and analyzed by flow cytometry. Samples were compared to 
equally treated ctrl. miRNA transfected cells (black histogram). Results are representative for at least three 
independent experiments. 
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3.5 miRNA-133b target identification 
3.5.1 Microarray and pSILAC analysis of mRNA and protein expression 
Following the determination and description of the pro-apoptotic nature of miRNA-
133b, the question concerning the target genes and their involvement in the process of 
apoptosis sensitization was approached. Given the fact that miRNA regulation may be 
executed at the mRNA (mRNA slicing) or protein level (translational arrest), a dual target 
discovery strategy was used. First, taking advantage of the clear cut phenotype observed in 
HeLa cells, anti-apoptotic genes being regulated at the mRNA-level were characterized. 
Whole genome microarray expression-analysis allowed the identification of mRNAs with 
impaired expression after miRNA-133 transfection. Pursuing the idea that miRNA-133b 
might primarily act by restraining the induction of canonical anti-apoptotic factors, 
transfected cells were stimulated with TNFα for 6 hours prior to RNA collection (Scheme 
11).  
 
 
Scheme 11. Microarray gene expression analysis of TNFα-stimulated ctrl. and miRNA-133b transfected cells 
 
Under these conditions a total of 213 genes emerged as down-regulated (FCH<-1.5; 
p-value<0.001). Consistent with results published by others the observed mRNA expression 
changes were not drastic and ranged between -1.5 and a minimum of -4.8 fold (Lim et al, 
2005). In order to categorize the obtained results, the list of potential target genes was 
analyzed and filtered according to two criteria: 1) in-silico sequence analysis for the presence 
of potential miRNA-133b binding sites 2) known pro- or/and anti-apoptotic features. For the 
first filter the prediction databases TargetScan and MicroCosm Targets were used (Friedman 
et al, 2009; Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005). The second 
filter was achieved by performing a gene functional classification using the database for 
annotation, visualization and integrated discovery (DAVID) (Dennis et al, 2003; Huang da et 
al, 2009a; Huang da et al, 2009b).  
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According to this filtering strategy 13 genes with the ability to regulate apoptotic 
responses were identified. Eight of these were predicted to harbor miRNA-133b binding sites 
in their 3´-UTR (Table 10). Of all 13 genes the pro-apoptotic ones were BCL2/adenovirus 
E1B 19kD-interacting protein 3-like (BNIP3L), Killer cell lectin-like receptor subfamily K 
member 1 (KLRK1), sulfatase 1 (SULF1), sphingosine-1-phosphate phosphatase 1 (SGPP1), 
cytoplasmic FMR1 interacting protein 2 (CYFIP2), growth arrest-specific gene-1 (GAS1), 
forkhead box L2 (FOXL2) and PHD finger protein 17 (PHF17). On the other hand, the list of 
anti-apoptotic genes consisted of OPG, FAIM, FASN and GSTP1. The latter group 
represented the most interesting set of target gene candidates, since miRNA-133b is an 
apoptosis promoting, but not repressing molecule. 
 
Table 10. Apoptosis regulatory genes down-regulated at the mRNA level in miRNA-133b transfected TNFα-
stimulated HeLa cells 
Accesion Gene name 1FCH Function 
2Predicted 
miRNA-133b 
Target 
 
NM_002546 
 
OPG 
 
-2.9 
 
anti-apoptotic 
 
no 
NM_004331 BNIP3L -2.4 pro/anti-apoptotic yes 
NM_007360 KLRK1 -2.3 pro-apoptotic yes 
NM_015170 SULF1 -2.2 pro-apoptotic yes 
NM_018147 FAIM -2.2 anti-apoptotic yes 
NM_004104 FASN -2.1 anti-apoptotic no 
NM_000852 GSTP1 -2.0 anti-apoptotic yes 
NM_030791 SGPP1 -1.9 pro-apoptotic no 
NM_014376 CYFIP2 -1.9 pro-apoptotic no 
NM_002048 GAS1 -1.8 pro-apoptotic no 
NM_023067 FOXL2 -1.7 pro-apoptotic yes 
NM_024900 
 
PHF17 
 
-1.7 
 
pro-apoptotic 
 
yes 
 
1 compared to ctrl. miRNA tranfected and TNFα-stimulated cells. p-value < 0.01 
2 As predicted by either TargetScan or MicroCosm Targets 
 
As the second step of the target identification strategy and to complement the 
microarray analysis, a global protein profile of miRNA-133b transfected cells was generated. 
To this end the recently developed pulsed stable isotope labeling by amino acids in cell 
culture (pSILAC) approach was used (Selbach et al, 2008). Briefly, pSILAC is based on the 
labeling of cells with amino acids of dissimilar molecular mass. Once labeled, the cells are 
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transfected with the miRNA of interest or a negative control and both protein samples are 
analyzed and compared by mass spectrometry. This allows the exact identification and 
quantification of the protein content present in each sample. By direct comparison of both 
samples it is possible to identify proteins whose expression is repressed in the sample 
transfected with the miRNA of interest. Such proteins constitute very interesting miRNA 
target candidates, since the diminished expression level could be a direct consequence of the 
miRNA treatment. In this particular case analysis of HeLa cells transfected with miRNA-
133b or the control miRNA was performed. Acting on the same assumption as for the 
microarray expression analysis, miRNA-133b and ctrl. miRNA transfected cells were also 
stimulated with TNFα for 6 hours prior to protein lysate harvest (Scheme 12).  
 
 
Scheme 12. pSILAC analysis of TNFα-stimulated ctrl. and miRNA-133b transfected cells. Based on (Selbach et 
al, 2008) 
 
Consistent with previous reports miRNA-133b transfection led only to overall mild 
effects on protein synthesis (Baek et al, 2008; Selbach et al, 2008). A total of 1480 proteins 
could be identified by mass spectrometry. Of these 25 displayed significant repression in the 
sample transfected with miRNA-133b and TNFα (Table 11). 19 proteins were predicted to 
comprise potential miRNA-133b binding sites, but only 6 correlated positively with the 
results obtained by microarray analysis (Table 10.). Among these, FASN and GSTP1 
constituted the most interesting candidates due to their anti-apoptotic roles and relative strong 
repression at the protein level (2.6 and 2.1 respectively). 
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Table 11. Apoptosis regulatory proteins down-regulated in miRNA-133b transfected TNFα-stimulated HeLa 
cells 
UniProt Name 1FCH repression 
Positive correlation 
with microarray 
analysis 
2Predicted miRNA-
133b Target 
 
TAGLN2 
 
4.2 
 
yes 
 
yes 
VIM 3.9 no no 
MYH9 2.7 yes yes 
FASN 2.6 yes no 
MYL12B 2.7 no yes 
CKAP4 2.3 yes yes 
NP 2.2 no yes 
PTBP1 2.2 yes yes 
GSTP1 2.1 yes yes 
MYL6 2.1 no no 
MSN 2.1 no yes 
SAE1 2 no no 
CPNE3 1.9 yes yes 
FSCN1 1.9 no yes 
CMPK1 1.8 no yes 
ARHGDIA 1.8 no yes 
CAP1 1.7 no yes 
MAT2B 1.7 no yes 
CARBP2 1.6 no no 
HMGCS1 1.6 no no 
IDH1 1.6 no yes 
NQO1 1.6 no yes 
RAB5C 1.6 no yes 
SERPINH1 1.5 no yes 
1 Fold-change   
2 As predicted by either TargetScan or MicroCosm Targets  
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3.5.2 Target validation 
 Based on the results delivered by microarray and pSILAC analyses, selected genes 
were chosen for further validation and characterization. These included the anti-apoptotic 
genes FAIM, OPG, FASN and GSTP1. For the miRNA target validation process an 
experimental strategy covering three different aspects was used. These were: i) in-silico gene 
sequence analysis and prediction of potential miRNA-133b binding regions ii) Experimental 
demonstration of the direct physical interaction between the miRNA and the predicted target 
sequence using a dual-luciferase reporter assay (see 2.2.6.1) iii) Characterization of the 
molecular mechanism (mRNA slicing or translational arrest) responsible for the expression 
repression mediated by miRNA-133b.  
 
 
3.5.2.1 miRNA-133b targets FAIM 
FAIM is a widely expressed and evolutionarily conserved anti-apoptotic protein 
originally cloned from B-cells and with protective traits against Fas-mediated apoptosis 
(Schneider et al, 1999). In-silico analysis of the 3’UTR region of FAIM predicted the 
presence of an exclusive miRNA-133b binding site characterized by strong complementarity 
to the miRNA seed region (nucleotides 2-7). According to the prediction algorithm 
TargetScan this sequence in the 3´-UTR of FAIM displays a low degree of conservation 
among mammals (Figure 9A). In order to test if miRNA-133b and its predicted target 
molecule interact with each other, mRNA luciferase reporter constructs were generated. 
Cloning of the complete 3’UTR of FAIM into the psiCHECK-2 luciferase reporter plasmid 
rendered the luciferase (Renilla reniformis) after co-transfection of miRNA-133b inactive by 
40%. As demonstrated by competition experiments, the interaction between the binding-site 
in the 3’UTR and miRNA-133b was sequence specific, since co-transfection of αmiRNA-133 
but not the control αmiRNA fully restored the activity of the Renilla reniformis luciferase 
(Figure 9B). Moreover, confirming the results obtained by microarray analysis, miRNA-133b 
transfection of HeLa cells translated into specific down-regulation of FAIM mRNA 
demonstrated by qPCR (Figure 9D). This led to 70% reduction of FAIM protein levels as 
evidenced by Western blot analysis (Figure 10C). Both effects were sequence specific and 
could be blocked by addition of a specific miRNA-133b inhibitor (Figure 9C and D). 
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Figure 9. Expression of the anti-apoptotic molecule FAIM is regulated by miRNA-133b.  
A) miRNA-133b target sites within the 3`UTR of FAIM as predicted by TargetScan and MicroCosm Targets. B) 
3´-UTR targeting assay. HeLa cells were co-transfected with different combinations of miRNA mimics and a 
luciferase reporter plasmid harboring the complete 3´-UTR of FAIM (psiCHECK2-FAIM). The template 
plasmid (psiCHECK2) was used as a negative and normalization control. Activity of the 3´-UTR -dependent 
luciferase (Renilla reniformis) was measured 48 hrs. post-transfection and normalized for transfection efficiency 
to the one produced by the miRNA- and 3´-UTR-independent luciferase (Photinus pyralis). Error bars = 
standard deviation C) Western blot and densitometric analysis of FAIM expression. Cells were transfected with 
miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a specific miRNA-133b inhibitor 
(αmiRNA-133b). After 48 hrs. cellular protein lysates were prepared and FAIM expression was assessed by 
Western blot. GAPDH was used as an internal loading standard. ctrl. miRNA transfected cells were used as a 
reference for densitometric quantification of protein band intensity. D) qPCR analysis of FAIM mRNA 
expression. Cells were transfected for 48 hrs. before total RNA was isolated, reverse transcribed and analyzed 
by qPCR for the expression of FAIM. Human acidic ribosomal protein (HuPO) was used as the house-keeping 
gene for internal normalization. qPCR values are shown relative to mock transfected cells incubated under the 
same conditions and were calculated by performing the ΔΔCt-method (Bookout et al, 2006). All graphs are 
representative of at least three independent experiments.  
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3.5.2.2 OPG expression is regulated by miRNA-133b 
OPG is a soluble extracellular protein that acts as a decoy receptor (DcR) for TRAIL 
and protects cells from TRAIL-induced apoptosis (Emery et al, 1998). As revealed by 
microarray analysis, treatment of HeLa cells with miRNA-133b led to a -2.9 fold down-
regulation of OPG transcripts (Table 10). This could be verified by qPCR analysis, where 
miRNA-133b treatment resulted in a specific reduction of up to three-fold of OPG mRNA 
levels 48 and 72 hrs. post-transfection (Figure 10A). In order to determine if the amount of 
protein was also impaired in a miRNA-133b dependent manner, enzyme linked 
immunosorbent assay (ELISA) was performed with cell culture supernatant of transfected 
cells. As a measure to avoid false positive results as a consequence of cytotoxicity caused by 
miRNAs or differential proliferation rates of transfected cells, MTT proliferation assay was 
used for normalizing the ELISA values to the amount of metabolically active cells per well. 
A reduction of 65 and 67% in the amount of secreted OPG at 48 and 72 hrs. after miRNA-
133b transfection was observed, respectively. Co-treatment of the cells with the interfering 
αmiRNA-133b, but not the ctrl. αmiRNA, reconstituted the levels of released OPG almost 
completely back to those of ctrl. miRNA transfected cells (Figure 10B). 
 
 
Figure 10. miRNA-133b is a post-transcriptional regulator of OPG.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). Cells transfected with a scrambled control miRNA (ctrl. 
miRNA) served as point of comparison. A) At the indicated time points total RNA was isolated, reverse 
transcribed and analyzed by qPCR for the expression of OPG. Human acidic ribosomal protein (HuPO) was 
used as the house-keeping gene for internal normalization. qPCR values are relative to mock transfected cells 
incubated under the same conditions and were calculated by performing the ΔΔCt-method (Bookout et al, 
2006). B) Cell culture supernatants of transfected cells were examined by ELISA for the presence of secreted 
OPG. At each time point, after collection of the supernatants a MTT assay was performed with the remaining 
cell layers. This was used for the normalization of the results obtained by ELISA. All graphs are representative 
of at least three independent experiments. Error bars = standard deviation 
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Unlike FAIM, analysis of the OPG 3´-UTR with several different target prediction 
databases did not reveal any potential miRNA-133 binding site. RNAhybrid is a tool for 
finding the minimum free energy hybridisation (mfe) of a long and a short RNA. The 
hybridisation is performed in a domain mode in which the short sequence is annealed to the 
best fitting part of the long one. The tool is primarily designed as a miRNA target prediction 
plattform (Rehmsmeier et al, 2004). Analysis of the 3’UTR of OPG with RNAhybrid 
pinpointed a single potential miR133b binding site (mfe = -18.8 kcal/mol) (Figure 11A; 
site I). Based on this, a luciferase reporter construct was generated and tested in co-
transfection experiments with miRNA-133b. As measured by dual-luciferase assay, cloning 
of the complete OPG 3’UTR into the reporter construct did not impair the luciferase (Renilla 
reniformis) activity in miRNA-133b transfectants (Figure 11B). As an additional attempt to 
identify other binding sites, the search for a binding site was expanded to the remaining 
regions of the mRNA, specially the 5’UTR, as it has been recently proposed that it might also 
be involved in miRNA-mediated gene silencing (Lee et al, 2009a). An additional potential 
interaction motive displaying better structural features (mfe = -27.1 kcal/mol) was mapped. 
Besides having a lower mfe than the site localized in the 3´-UTR, this potential target 
sequence is localized exactly two nucleotides up-stream of the OPG start codon (Figure 11A; 
site II) which suggests that binding of miRNA-133b to this site might interfere with mRNA 
translation. In order to test this hypothesis special luciferase constructs were generated (see 
2.2.6.2). Despite several attempts, manipulation of this region of the reporter plasmid always 
led to inactive luciferase transcription. Therefore, it was not possible to assess the importance 
of this sequence for miRNA-133b-mediated impairment of OPG expression  
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Figure 11. In-silico and in-vitro analysis of miRNA-133b binding sites in the OPG mRNA.  
MiRNA-133b target sites within the 3´ and the 5´UTR of OPG as predicted by RNAhybrid B) 3´ and 5´UTR 
targeting assay. HeLa cells were co-transfected with different combinations of miRNA mimics and a luciferase 
reporter plasmid harboring the complete 3´-UTR of OPG (psiCHECK2-OPG). The template plasmid 
(psiCHECK2) was used as a negative and normalization control. Activity of the 3´-UTR -dependent luciferase 
(Renilla reniformis) was measured 48 hrs. post-transfection and normalized to the one produced by the miRNA- 
and 3´-UTR -independent luciferase (Photinus pyralis). Results are representative of at least three independent 
experiments. Error bars = standard deviation. Arrow representes the translation inititation at the start codon. 
 
Since OPG is an inhibitor of TRAIL-triggered apoptosis, it was possible that the 
hyperresponsiveness displayed by miRNA-133b transfected HeLa cells (Figure 5,6,7 and 8) 
was partly attributed to the diminished quantity of this decoy receptor in the supernatant. To 
verify this hypothesis, reconstitution experiments with recombinant human OPG (rhOPG) 
were performed with HeLa cells transfected with a ctrl. miRNA or miRNA-133b. 48 hrs. 
after transfection the cells were stimulated with rhTRAIL and either 100 or 1000 ng/ml 
rhOPG. As evidenced by PI-incorporation assays (Figure 12A) and measurement of the 
activation status of CASP8 and 3 (Figure 12B), addition of rhOPG to the culture medium was 
able to revert the exacerbated TRAIL-induced apoptotic response characteristic of miRNA-
133b transfected cells. In case of the results provided by both readout systems the magnitude 
of the remaining apoptotic response corresponded exactly to that from control miRNA 
transfected TRAIL-stimulated vehicle-treated cells. This suggests that down-regulation of 
OPG by miRNA-133b is not the only mechanism contributing to the enhanced apoptotic 
response triggered by this DR ligand. 
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Figure 12. Recombinant OPG constrains the exacerbated TRAIL-responsiveness of miRNA-133b transfected 
cells.  
Cells were transfected with a ctrl. miRNA or miRNA-133b mimic and incubated for 48 hrs. Transfected cells 
were stimulated with 20 ng/ml recombinant human TRAIL (rhTRAIL) both in the absence (vehicle: H2O) or 
presence of 100 or 1000 ng/ml recombinant human OPG (rhOPG). A) Stimulated cells were collected, stained 
with propidium iodide (PI) and analyzed by flow cytometry. Samples were compared to unstimulated ctrl. 
miRNA transfected cells (black histogram). B) Treated cells were harvested, stained and scanned by flow 
cytometry for the presence of cleaved active CASP8 (upper graph) and 3 (lower graph). Cells transfected with 
ctrl. miRNA alone were used as a reference. Results are representative for at least three independent 
experiments. Errors bars = standard deviation. 
 
 
3.5.2.3 FASN and GSTP1: two oncogenes regulated by miRNA-133b 
FASN represents a very versatile enzyme fulfillling key tumorigenic functions 
(Menendez & Lupu, 2007). Microarray analysis of overall gene expression and mass 
spectrometric quantification of protein levels revealed reduced levels of FASN mRNA and 
protein in miRNA-133b transfected cells (Table 10 and 11). To validate these observations 
gene-specific qPCR and Western blot analysis of FASN were performed. Supporting the 
results obtained from the high-throughput approaches, treatment of HeLa cells with miRNA-
133b reduced the levels of FASN mRNA in a sequence specific manner. This translated to 
60% reduction at the protein level for single miRNA-133b transfected cells and, 20% when 
co-transfected with an unspecific αmiRNA. Introduction of the specific inhibitor of miRNA-
133b instead, rescued and enhanced the production of FASN protein (Figure 13A and B).  
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Figure 13. FASN expression is impaired by miRNA-133b.  
Cells were transfected with miRNA-133b alone or together with a control antimiRNA (ctrl. αmiRNA) or a 
specific miRNA-133b inhibitor (αmiRNA-133b). Cells transfected with a scrambled control miRNA (ctrl. 
miRNA) served as point of comparison. A) Total RNA was isolated, reverse transcribed and analyzed by qPCR 
for the expression of FASN 48 hrs. after introduction of the miRNA mimics in HeLa cells. Human acidic 
ribosomal protein (HuPO) was used as the house-keeping gene for internal normalization. qPCR values are 
relative to mock transfected cells incubated under the same conditions and were calculated by performing the 
ΔΔCt-method (Bookout et al, 2006). B) Western blot and densitometric analysis of FASN expression. Cell 
protein lysates were prepared 48 hrs. post-transfection and FASN expression was assessed by Western blot. 
GAPDH was used as an internal loading control. Cells transfected with ctrl. miRNA were used as a reference 
for densitometric quantification of protein band intensity. All graphs are representative of at least three 
independent experiments.  
 
In an effort to better dissect the molecular interaction between miRNA-133b and 
FASN mRNA, a miRNA-133b binding-site sequence analysis using RNAhybrid was 
performed. According to it, two potential binding regions with favorable biophysical 
characteristics (low mfe) were localized within the FASN mRNA. The first of them 
represented a canonical target site localized in the 3´-UTR of the transcript with an mfe of -28 
kcal/mol (Figure 14A, site I). As assessed by luciferase assay in HeLa cells, cloning of the 
complete 3´-UTR of FASN into a reporter plasmid did not impair luciferase expression after 
co-transfection of miRNA-133b (Figure 14B). The second predicted binding site displayed an 
almost perfect complementarity to miRNA-133b (mfe = -33.6 kcal/mol) and was located 
within exon 33 of FASN cds (Figure 14, site II). Due to lack of an appropriate experimental 
system for validating miRNA targeting of sequences located within the cds of genes, a first 
attempt to prove the potential binding capacity of miRNA-133b to this site was assessed by 
introducing it as artificial 3´-UTR into psiCHECK2. According to luciferase reporter assay, 
co-transfection of HeLa cells with this construct and miRNA-133b did not affect the 
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production of Renilla luciferase, when compared the unmodified plasmid (Figure 14B). 
Hence the exact molecular mechanism by which miRNA-133b down-regulates the expression 
level of FASN could not be fully elucidated.  
 
 
Figure 14. Sequence analysis of miRNA-133b binding sites within the FASN mRNA.  
A) Predicted miRNA-133b target sites within the 3`UTR and the coding sequence (cds) of FASN as calculated 
by RNAhybrid B) miRNA-133b targeting assay. HeLa cells were co-transfected with different combinations of 
miRNA mimics and luciferase reporter plasmids harboring either the complete 3´-UTR of FASN (psiCHECK2-
FASN) or the predicted target region in the cds (psiCHECK2-FASN_from_cds). The template plasmid 
(psiCHECK2) was used as a negative and normalization control. Activity of the 3´-UTR -dependent luciferase 
(Renilla reniformis) was measured 48 hrs. post-transfection and normalized to the one produced by the miRNA- 
and 3´-UTR -independent luciferase (Photinus pyralis). Results are representative of at least three independent 
experiments. Error bars = standard deviation. 
 
GSTP1 is an ubiquitously expressed protein that plays an important role in 
detoxification and xenobiotics metabolism (Wu et al, 2006). As predicted by TargetScan and 
MicroCosm Targets, GSTP1 has one poorly conserved miRNA-133b binding site in its 3´-
UTR (Figure 15A). To confirm this, a 3´-UTR targeting luciferase reporter plasmid was 
constructed. Co-transfection of HeLa cells with the plasmid and miRNA-133b showed ~40% 
reduction of luciferase (Renilla reniformis) activity. Supporting a direct interaction between 
miRNA-133b and the cloned target sequence, co-treatment with a specific αmiRNA, but not a 
negative control, restored full enzymatic activity (Figure 15B). To further test the regulatory 
role of the molecular interaction between miRNA-133b and the 3´-UTR of GSTP1, mRNA 
and protein levels were determined after miRNA transfection. qPCR analysis confirmed a 
miRNA-133b dependent 2.3 fold reduction of the mRNA coding for GSTP1 (Figure 15D). 
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Accordingly, transfected cells showed 50% less GSTP1 protein (Figure 15C). Both 
observations matched the results obtained by microarray and pSILAC analysis (Table 10 
and 11) providing a further line of evidence for the regulatory role of miRNA-133b over 
GSTP1 expression. Hence, miRNA-133b is a pro-apoptotic molecule with the ability to 
impair the expression of important oncogenes. 
 
 
Figure 15. GSTP-1 expression is miRNA-133b dependent.  
A) miRNA-133b target site within the 3´-UTR of GSTP1 as predicted by TargetScan and MicroCosm Targets. 
B) 3´-UTR targeting assay. HeLa cells were co-transfected with different combinations of miRNA mimics and a 
luciferase reporter plasmid harboring the complete 3´-UTR of GSTP1 (psiCHECK2-GSTP1). The template 
plasmid (psiCHECK2) was used as a negative and normalization control. Activity of the 3´-UTR -dependent 
luciferase (Renilla reniformis) was measured 48 hrs. post-transfection and normalized to the one produced by 
the control and 3´-UTR -independent luciferase (Photinus pyralis). Error bars = standard deviation. C) Western 
blot and densitometric analysis of GSTP1 expression. Cells were transfected with miRNA-133b alone or 
together with a control antimiRNA (ctrl. αmiRNA) or a specific miRNA-133b inhibitor (αmiRNA-133b). 48 
hrs. later cellular protein lysates were prepared and GSTP1 expression was assessed by Western blot. GAPDH 
was used as an internal loading control. Cells transfected with ctrl. miRNA were used as a reference for 
densitometric quantification of protein band intensity. D) qPCR analysis of GSTP1 mRNA expression. Cells 
were transfected for 48 hrs. before total RNA was isolated, reverse transcribed and analyzed by qPCR for the 
expression of GSTP1. Human acidic ribosomal protein (HuPO) was used as the house-keeping gene for internal 
normalization. qPCR values are relative to mock transfected cells incubated under the same conditions and were 
calculated by performing the ΔΔCt-method (Bookout et al, 2006). All graphs are representative of at least three 
independent experiments.  
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3.6 Activation of the innate immune response induces miRNA-133b expression 
 After having characterized the pro-apoptotic response mediated by miRNA-133b and 
having pinpointed several of the molecular mechanisms and interactions that account for it, 
the next aim was to gain a deeper insight into the regulation of miRNA-133b expression. The 
levels of several miRNAs have been previously demonstrated to depend strongly on 
activation of the innate immune system e.g. through stimulation of Toll-like receptors (TLRs) 
(O'Connell et al, 2007; Sheedy & O'Neill, 2008; Tili et al, 2007). To investigate whether 
miRNA-133b expression can be influenced by triggering the innate immune response, human 
THP1 macrophages were stimulated with various different TLR ligands. After stimulation 
total RNA was extracted from the cells and the expression level of miRNA-133b was 
analyzed by gene-specific qPCR. As a point of comparison the amount of miRNA-146a, a 
molecule well known to be strongly up-regulated during the pro-inflammatory response, was 
determined.  
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Figure 16. Expression levels of miRNA-133b and -146a after TLR stimulation.  
THP1 macrophages were stimulated with 100 ng/ml Pam3CSK4, 108 cells/ml heat-killed Listeria 
monocytogenes (HKLM), 10 µg/ml poly(I:C), 100 ng/ml lipopolysaccharide (LPS), 1 µg/ml S. typhimurium 
flagellin, 100 ng/ml FSLI, 1 µg/ml imiquimod, 1 µg/ml ssRNA40 or 10 µg/ml CpG ODN2006. After 6 hrs. of 
stimulation cells were collected and total RNA was extracted. miRNA-specific qPCR was performed with 
RNU6B as an internal normalization control. Values represent the miRNA expression levels compared to 
unstimulated cells and were calculated by performing the ΔΔCt-method (Bookout et al, 2006).  
Results 
65 
 
 In accordance to the results obtained by several other groups, activation of almost all 
TLRs led to increased levels of miRNA-146a. Treatment of cells with some specific stimuli 
also resulted in enhanced miRNA-133b expression. Activation with HKLM led to 8 fold 
increase, whereas eliciting of TLR1/2, 7, 6 and 9 with Pam3CSK4, imiquimod, ssRNA or 
CpG, respectively, showed less pronounced effects that ranged between twofold to fourfold 
induction (Figure 16). Notably, priming of the macrophages with poly(I:C), the cognate 
ligand of TLR3, provoked a 15 fold enhancement of miRNA-133b production. To test 
whether this was also the case in the cell system used so far, HeLa cells were treated with 
poly(I:C) and subsequently analyzed for the abundance levels of both miRNA-133b and -
146a. Triggering of TLR3 in these cells, known to express all TLRs (Nishimura & Naito, 
2005), led to 15 and 7 times more miRNA-133b and -146a respectively (Figure 17). In 
summary, miRNA-133b expression depended on activation of the innate immune system. 
 
poly(I:C)
1
5
9
13
17
21 miRNA-133b
miRNA-146a
FC
H
 
 
Figure 17. TLR3 activation of HeLa cells enhances miRNA-133b and -146a expression.  
HeLa cells were stimulated. with 10 µg/ml poly(I:C) for 6 hrs. Primed cells were collected and total RNA was 
extracted. miRNA-specific qPCR was performed with RNU6B as an internal normalization control. Values 
represent the miRNA expression levels compared to unstimulated cells and were calculated by performing the 
ΔΔCt-method (Bookout et al, 2006).  
 
 
3.7 miRNA-133b leads to enhanced NF-κB activity 
Currently, the best characterized function of miRNAs whose expression is enhanced 
by TLR ligation is the down-regulation of key molecules of the signaling cascades that mount 
the innate immune response. By doing this, miRNAs provide a negative feedback mechanism 
that protects both the cell and organism from harmful exacerbated pro-inflammatory 
responses (Hou et al, 2009; Liu et al, 2009a; Taganov et al, 2006). NF-κB activation 
constitutes the most prominent step after TLR activation leading to establishment of an 
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inflammatory response. To test whether miRNA-133b can influence the activation level of 
NF-κB, luciferase activity assays were performed. To this end, HeLa cells were co-
transfected with a reporter plasmid expressing the Photinus pyralis luciferase in an NF-κB 
dependent manner and different combinations of miRNA mimics (Yang et al, 1998). Two 
days after treatment the samples were either left untreated or stimulated with TNFα or 
poly(I:C) in order to assess the activation status of NF-κB. Introduction of miRNA-133b into 
HeLa cells led to enhanced NF-κB activity after TNFα or poly(I:C) treatment. MiRNA-133b 
transfectants were characterized by an average increase in NF-κB activity of about three and 
a half times after TNFα-stimulation and seven times after poly(I:C) treatment. This 
enhancement was particular for miRNA-133b and could be inhibited by addition of a 
sequence specific inhibitory αmiRNA, but not a scrambled one (Figure 18A). As an attempt 
to indirectly determine the activation stage of NF-κB, expression of two major pro-
inflammatory targets was determined by qPCR. Supporting the results obtained with the 
luciferase assay, cells transfected with the miRNA-133b expressed four and seven times more 
interleukin 6 (IL6) and 8 (IL8) after TNFα-stimulation, respectively (Figure 18B). 
 
Figure 18. miRNA-133b enhances NF-κB activation and pro-inflammatory cytokine synthesis.  
A) HeLa cells were co-transfected with different combinations of miRNA mimics and a NF-κB dependent 
luciferase (Photinus pyralis) reporter plasmid. A plasmid expressing the Renilla reniformis luciferase was also 
introduced as transfection efficiency normalizing control. Transfected cells were incubated for further 48 hrs. 
before they were either left untreated or primed for 4 hrs. with 20 ng/ml TNFα or 10 µg/ml poly(I:C). Cells 
transfected with ctrl. miRNA were used as a reference point for each different type of treatment. For assessing 
the activation status of NF-κB, all samples were lysed and dual-luciferase assay was performed. Error bars = 
standard deviation. B) Cells were transfected with a control miRNA (ctrl. miRNA) or miRNA-133b and kept for 
48 hrs. Following incubation, samples were treated with 20 ng/ml TNFα for 4 hrs. Primed cells were collected 
and total RNA was extracted. qPCR analysis of interleukin 6 and 8 (IL6/8) was performed using human acidic 
ribosomal protein (HuPO) as an internal normalization control. Values represent the gene expression levels 
compared to ctrl. miRNA transfected TNFα-treated cells and were calculated by performing the ΔΔCt-method 
(Bookout et al, 2006). All graphs are representative of at least three independent experiments.  
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 Within the miRNA research field miRNA-146a constitutes the best characterized 
example of an immunoregulatory molecule that acts by down-modulating the expression of 
key signaling molecules. miRNA-146a serves as a negative regulator of NF-κB mediated 
inflammation by impairing the signal transduction by targeting of indispensable genes such as 
IRAK1/2 and TRAF6 (Hou et al, 2009; Perry et al, 2008; Taganov et al, 2006; Williams et al, 
2008). To test, whether miRNA-146a was able to block the enhanced NF-κB activity 
mediated by miRNA-133b, NF-κB luciferase reporter assays of cells transfected with the 
miRNA-133b in combination with miRNA-146a were performed after TNFα- or poly(I:C)-
stimulation. In both cases, co-transfection of miRNA-146a mimicked the effect of αmiRNA-
133b by completely abolishing the enhanced NF-κB activity characteristic of miRNA-133b 
transfectants (Figure 19).  
 
 
 
Figure 19. miRNA-146a blocks miRNA-133b mediated enhanced NF-κB activity.  
A) HeLa cells were co-transfected with different combinations of miRNA mimics and a NF-κB dependent 
luciferase (Photinus pyralis) reporter plasmid. A plasmid expressing the Renilla reniformis luciferase was also 
introduced as transfection efficiency normalizing control. Transfected cells were incubated for further 48 hrs. 
before they were either left untreated or primed for 4 hrs. with 20 ng/ml TNFα or 10 µg/ml poly(I:C). Cells 
transfected with ctrl. miRNA were used as a reference point for each different type of treatment. For assessing 
the activation status of NF-κB, all samples were lysed and dual-luciferase assay was performed. Error bars = 
standard deviation. This result is representative for at least three independent experiments. 
 
Summing up, miRNA-133b was able to improve the activation of NF-kB, leading to 
increased expression of pro-inflammatory cytokines. This implied that the expression of 
negative regulators of NF-κB might be impaired by miRNA-133b. Despite several attempts 
the identity of this molecule has remained elusive and further elaborated approaches are 
required. 
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4. Discussion 
Ever since lin-4, the first identified miRNA, was discovered in 1993 (Lee et al, 1993; 
Wightman et al, 1993), this family of previously unknown molecules has earned a 
superordinate position among the central mechanisms of gene activity regulation. Since 
computational analyses predict that the expression of up to 30% of all genes is regulated by 
miRNAs, it is likely that they are involved in the control of all biological processes (Bartel & 
Chen, 2004). This work summarizes the results obtained by a series of experimental attempts 
aimed at identifying and characterizing miRNAs with immunomodulatory and apoptosis 
regulatory properties. This venture led to conclusive mechanistic evidence for miRNA-133b 
as a very versatile regulator of pro-apoptotic signaling events triggered by members of the 
TNFR superfamily and their ligands. The data presented herein constitute the first example of 
a single miRNA with the ability to influence all three major pathways of DR mediated 
apoptosis. In the following the relevance of these findings will be discussed within the 
context of current miRNA and immunological research. 
 
 
4.1 miRNA-133b is a novel regulator of death receptor mediated apoptosis 
Despite tremendous efforts to unravel the role of miRNAs as fine tuners of cellular 
fate and differentiation, to date only scant mechanistic evidence of their involvement in DR-
triggered apoptosis exists. In the context of TNFα-induced apoptosis the only known example 
of miRNA involvement refers to the sensitization to TNFα cytotoxicity displayed by human 
embryonic kidney cells over-expressing the miRNA cluster miR-23a~27a~24-2 (Chhabra et 
al, 2009). Unfortunately, exact molecular mechanisms responsible for the increased 
apoptosis, i.e. target genes being down-regulated, still remain to be identified. With respect to 
the apoptotic response mediated by Fas it has been described that treatment of T-cells with an 
activating Fas-antibody induced expression of miRNA-143 in a time-dependent manner. 
Furthermore, over-expression of this miRNA in Jurkat cells translated to impaired 
proliferation and enhanced FasL-mediated apoptosis. In this case targeting of extracellular 
signal-regulated protein kinase 5 (ERK5) was proposed as the mechanism allowing a positive 
death-promoting feedback loop (Akao et al, 2009). The influence of miRNAs on DR-
signaling has been mechanistically best characterized for the apoptosis inducing system 
composed of TRAIL and its receptors. At least ten different miRNAs have been identified as 
potential regulators (Corsten et al, 2007; Lu et al, 2009; Mott et al, 2007; Ovcharenko et al, 
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2007). Among these miRNA-221 und -222 were recently reported as over-expressed in more 
aggressive compared to less invasive tumors. It could be shown that these two miRNAs 
induce TRAIL resistance through targeting of phosphatase and tensin homolog (PTEN) and 
tissue inhibitor of metalloproteinases 3 (TIMP3) (Garofalo et al, 2009).  
 
Herein, an ex-vivo model system of DR-triggered apoptosis was used to expand the 
knowledge on miRNA-based regulation of this key signaling pathway. By doing this 
miRNA-133b was characterized as a many-sided molecule with the ability to enhance 
cytotoxic responses triggered by TNFα, FasL or TRAIL. Encoded on the sixth human 
chromosome miRNA-133b and -206 compose a bicistronic miRNA cluster originally 
considered to be exclusively expressed in skeletal muscle (McCarthy, 2008). Recent reports 
support a broader expression pattern of both cluster members, and attribute miRNA-206 
important regulatory functions in regions as different as brain, skeletal muscle or adipose 
tissue (Anderson et al, 2006; Hansen et al, 2007; Walden et al, 2009; Williams et al, 2009). 
Recently, miRNA-206 was brought into the context of apoptosis and cell cycle regulation by 
two independent publications demonstrating its capacity to promote apoptosis and to 
negatively regulate cell cycle progression (Adams et al, 2009; Song et al, 2009). In contrast to 
this profound mechanistic characterization of miRNA-206, miRNA-133b, the other cluster 
member, has remained by and large uninvestigated.  
 
As demonstrated by our findings, the strong apoptotic response generated by 
transfection of miRNA-133b into HeLa cells is a direct consequence of multiple synergistic 
alterations of their protein repertoire i.e. miRNA-133b impairs the expression and function of 
various important anti-apoptotic genes. Here clear-cut evidence for FAIM as a target gene of 
miRNA-133b was provided since miRNA-133b transfection led to 70% reduction of FAIM 
protein levels in a sequence specific manner (Fig 9C). Originally discovered during a screen 
aiming to identify factors responsible for Fas-resistance in primary splenic B cells, FAIM has 
emerged as a highly conserved atypical regulator of DR-mediated apoptosis (Schneider et al, 
1999). Presently almost no information is available about the mechanisms by which FAIM 
exerts its protective function. Its unique structure, with no significant primary sequence 
homology to any other known protein domains, does not allow any detailed mechanistic 
insight (Hemond et al, 2009). FAIM knockout mice are viable and have normal B- and T-cell 
populations. However, faim-/-B cells and thymocytes show increased sensitivity to Fas-
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triggered apoptosis in-vitro, and faim-/- mice suffer from greater mortality and exhibit 
exacerbated liver damage in response to Fas engagement in-vivo. Moreover, deletion of 
FAIM in mice results in greater activation of CASP8 and 3 and augmented PARP cleavage in 
FasL-stimulated, but not in dexamethasone, TNFα or γ-irradiated thymocytes (Huo et al, 
2009). This resembles the phenotype observed in miRNA-133b transfected HeLa cells, where 
stimulation of the cells with an activating αCD95 antibody caused massive caspase activation 
and subsequent PARP degradation. At the same time, the observation made in the knockout 
mice implies that sensitization to TNFα detected in miRNA-133b transfected cells, as well as 
their enhanced responsiveness to TRAIL-stimulation, is probably not a direct consequence of 
FAIM down-regulation. 
 
So far, two FAIM isoforms have been discovered. FAIM-L, the long variant, is 
present almost exclusively in neurons, whereas the short one (FAIM-S) displays a broader 
expression pattern (Segura et al, 2007; Zhong et al, 2001). Over-expression studies in neurons 
revealed a protective role of FAIM-L against TNFα and FasL mediated apoptosis upstream of 
both CASP8 and 3 and, the ability of FAIM-S to promote neurite outgrowth by a mechanism 
involving the activation NF-κB (Segura et al, 2007; Sole et al, 2004). Notably, both FAIM 
isoforms share the same 3’UTR containing one miRNA-133b binding site, implying that both 
protein variants could be subjected to post-transcritpional regulation by this miRNA. In fact, 
enriched presence of miRNA-133b was recently identified in the midbrain, where it regulates 
the maturation and function of dopaminergic neurons (Kim et al, 2007). Based on this and the 
miRNA-targeting evidence provided here, future work should investigate the importance of 
the down-modulation of FAIM by miRNA-133b during DR-triggered apoptosis and neuron 
development in the midbrain.  
 
Two more functional attributes of FAIM have been characterized. First, in-vivo FAIM 
influences positively the expression of the key anti-apoptotic molecule cFLIP in lymphocytes 
and hepatocytes (Huo et al, 2009). cFLIP is known to antagonize Fas-signaling by interfering 
with recruitment of procaspase 8 (proCASP8) to the DISC (Scaffidi et al, 1999a). Reduced 
levels of cFLIP would allow a better physical interaction of proCASP8 with Fas thus leading 
to better caspase activation and probably enhanced apoptosis (Huo et al, 2009). To test, 
whether this was also the case in miRNA-133b transfected cells, cFLIP expression was 
analyzed (data not shown). No significant difference of cFLIP between ctrl. miRNA and 
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miRNA-133b transfected cells could be observed at the mRNA or protein level. A possible 
explanation for this could be that generation of a knockout mouse leads to complete absence 
of the deleted gene, whereas transient miRNA treatment merely results in a partial reduction 
(~70%) of protein expression (Figure 9). Therefore, miRNA-133b transfected cells might still 
contain sufficient FAIM to assure the expression of cFLIP. This would mean that induction 
of cFLIP expression is not the only mechanism by which FAIM protects cells from cytotoxic 
signals triggered by DR ligands. On the other hand, as observed in the FAIM knockout 
mouse, it is also feasible that up-regulation of cFLIP by FAIM is a specific anti-apoptotic 
mechanism of hepatocytes, thymocytes and B-lymphocytes. The second recently described 
FAIM function refers to its ability to enhance, both ex- and in-vivo, CD40 signaling for NF-
κB activation, interferon regulatory factor 4 (IRF4) expression and B-cell lymphoma 6 
(BCL6) down-regulation during B-cell differentiation processes (Kaku & Rothstein, 2009). 
Since miRNA-133b represents the first identified post-transcriptional regulator of this anti-
apoptotic molecule and, considering the high degree of conservation across different species 
of both miRNA-133b and FAIM, it would be interesting to assess the relevance of miRNA-
133b for processes associated to B-cell development. 
 
Further evidence for the relevance of miRNA-133b as a controller of DR-mediated 
apoptosis was provided by the experiments presented here showing that it duplicates the 
apoptotic response induced by TRAIL in transiently transfected HeLa cells (Figures 5, 6, 7 
und 8). OPG was originally described as a soluble decoy receptor with proficiency to inhibit 
osteoclast differentiation by interfering with the signaling system involving receptor activator 
of NF-κB (RANK) and its ligand (RANKL) (Leibbrandt & Penninger, 2008). Later on, with 
the discovery that OPG can also bind to TRAIL, it emerged as an important anti-apoptotic 
and tumor survival factor (Emery et al, 1998; Holen & Shipman, 2006). In this work it could 
be established that miRNA-133b impairs OPG transcription and expression. Hence, ~70% 
less decoy molecules are secreted to the medium by transfected cells (Figure 10). By adding 
the recombinant human OPG to the culture medium, it was possible to reconstitute the 
TRAIL resistance of miRNA-133b transfected cells. Importantly, despite addition of OPG 
significantly higher apoptosis levels were still observed in miRNA-133b transfectants, 
compared to equally stimulated ctrl. miRNA transfected cells (Figure 12). This suggests that 
impaired OPG expression is not the only mechanism contributing to exacerbated TRAIL 
responsiveness. This was further supported by the fact that specific down-regulation of OPG 
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using small-interfering RNAs (siRNAs) was not sufficient for mimicking the enhanced 
reactivity to TRAIL mediated by miRNA-133b (data not shown). Hence, the strong pro-
apoptotic influence of miRNA-133b on TRAIL-mediated signaling is rather the consequence 
of pleiotropic down-modulation of gene activity, rather than being mediated by reduced 
activity of one single genetic entity.  
 
Since OPG has a very strong affinity for RANKL, it is feasible that miRNA-133b 
mediated regulation of this decoy receptor might also be relevant in some of the numerous 
biological processes controlled by this cytokine. In line with this idea, it was recently shown 
that miRNA-206, the molecule belonging to the same cluster as miRNA-133b, performs 
important functions during osteoblast differentiation (Inose et al, 2009). Since OPG is a key 
player during the process of bone generation and resorption, and given that miRNA-133b 
should be co-expressed with miRNA-206, it is interesting to speculate on a possible function 
of the molecular regulatory system described in this work during skeletal remodeling.  
 
Recently, further mechanistic evidence of a pro-apoptotic function of miRNA-133b 
was discovered. According to it, miRNA-133b is a potent death-promoting molecule that 
impairs the expression of the anti-apoptotic genes MCL1 and BCL-w. By doing this, 
miRNA-133b jeopardizes the preservation of mitochondrial membrane integrity during drug-
induced apoptosis (Crawford et al, 2009). Importantly, this identification of miRNA-133b as 
a sentinel of the endogenic apoptotic pathway upholds the findings presented in this thesis. It 
strengthens the notion of miRNA-133b as death-promoting factor that fulfills its task by 
impairing the correct function of pro-survival responses on different levels from both 
endogenic and exogenic apoptotic pathways.  
 
 
4.2 Tumor suppressor activity of miRNA-133b 
Cancer is a complex genetic disease caused by the accumulation of mutations, which 
lead to deregulation of gene expression and uncontrolled cell proliferation (Lee & Dutta, 
2009). During the last years huge amounts of experimental evidence have accumulated that 
support the tight link between tumorigenesis and miRNA expression and function (Esquela-
Kerscher & Slack, 2006; Lee & Dutta, 2009). The importance of miRNAs for cancer 
development is highlighted by the fact that approximately 50% of the genes encoding 
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miRNAs are located in cancer associated genomic regions or fragile sites, which are 
frequently amplified or deleted in tumors (Calin et al, 2004; Sevignani et al, 2007). 
According to their molecular function miRNAs can be classified as oncogenic or tumor-
suppressing. One important example of a miRNA with tumorigenic activity is miRNA-21. It 
is up-regulated in almost all kinds of cancer where it inhibits apoptosis, promotes growth and 
induces a metastatic phenotype (Selcuklu et al, 2009). On the other hand, tumor-suppressing 
miRNAs like miRNA-15, -29 or -34b/c can show a reduced expression or even complete 
absence in neoplastic tissues. As common characteristic, most of them induce cell-growth 
arrest and enhance the apoptosis sensitivity of the tumors (Cimmino et al, 2005; Mott et al, 
2007; Raver-Shapira et al, 2007).  
 
Herein, it was demonstrated that miRNA-133b causes apoptosis and is therefore likely 
to have potent tumoricidal properties. According to this, one would expect that the expression 
levels of this miRNA should be reduced in cancerous tissue compared to healthy one. Indeed, 
all miRNA profiles of different cancer types published so far, in which miRNA-133b has 
been detected as differentially regulated, concur in a lower expression of this molecule in 
diseased tissue (see appendix 7.1). Some tumor types displaying this characteristic include 
ovary, breast, head and neck/oral, bladder, colorectal, testes and lung cancer (Bandres et al, 
2006; Crawford et al, 2009; Kozaki et al, 2008; Navon et al, 2009; Tran et al, 2007; Wong et 
al, 2008a; Wong et al, 2008b). Thus, based on our data and considering the consistent down-
regulation of miRNA-133b in different cancers affecting different types of organs, it is 
feasible to postulate the impairment of miRNA-133b expression as one of the multiple steps 
leading to tumor formation. In other words, reduced levels of miRNA-133b would favor 
tissue transformation by protecting cancerous cells from apoptosis. In the future it would be 
interesting to study this in more detail using mice models in which miRNA-133b locus has 
been genetically ablated.  
 
In addition to FAIM and OPG other key genes whose expression is affected by 
miRNA-133b could be pinpointed in this work. The fact that transfection of miRNA-133b 
into HeLa cells resulted in 60 and 50% less FASN and GSTP1, respectively, stresses its 
importance as tumor suppressor (Figures 13 and 15). FASN is a central metabolic enzyme 
responsible for the final catalytic step during fatty acid synthesis. Compared with normal 
tissues, where FASN expression is very low, cancerous cells display much higher levels of it 
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(Kuhajda et al, 1994; Milgraum et al, 1997). In tumors, FASN plays important tumorigenic 
functions some of which include the generation of phospholipids needed for the cell 
membrane synthesis of fast growing cancer cells, formation of raft-aggregates implicated in 
key cellular and pro-survival signaling processes and prevention against accumulation of the 
tumoricidal sphingolipid ceramide (Bandyopadhyay et al, 2006; Pizer et al, 1996; Swinnen et 
al, 2003) (Scheme 13). From this perspective, miRNA-133b mediated suppression of FASN 
expression is very important, since it impairs the proliferation capacity of cancer cells. 
Moreover, it renders tumors more prone to cell death both without and after DR stimulation. 
The former is relevant for the studies presented in this work, since it would explain why 
unstimulated miRNA-133b transfected cells displayed low but still significantly higher levels 
of apoptosis, compared to ctrl. miRNA transfected cells. This idea is supported by results 
obtained from chemical inhibition and gene knock-down experiments, which to some extent 
resemble miRNA-mediated gene silencing, where FASN inhibition resulted in CASP8 
mediated tumor cell apoptosis (Knowles et al, 2008).  
 
 
Scheme 13. FASN inhibition activates several mechanisms leading to tumor cell death (Menendez & Lupu, 
2007) 
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GSTP1 belongs to a family of enzymes responsible for detoxification and protection 
of cells from harmful reactive species (Townsend & Tew, 2003). Of importance, GSTP1 
expression is highly elevated in neoplastic tissue and has been implicated in resistance to 
apoptosis (Cumming et al, 2001). Recently, GSTP1 was reported to regulate TNFα triggered 
signaling through interaction with TNF receptor-associated factor 2 (TRAF2) both ex- and in-
vivo. As a consequence of this, activation of apoptosis signal-regulating kinase 1 (ASK1) is 
impaired and, an essential axis for TNFα mediated apoptosis is blocked (Wu et al, 2006). 
Hence, by modulating the expression of two important oncogenes like FASN and GSTP1, 
miRNA-133b jeopardizes the ability of highly proliferating tumors to manage chemical stress 
and to self-supply with essential biomolecules. This feature together with the ability to 
control actively the sensitivity of cells to DR-stimulation may explain why down-regulation 
of miRNA-133b is a common feature in several different tumor types. 
 
 
4.3 miRNA-133b involvement during the innate immune response 
 In the context of innate immunity accumulating evidence has revealed pivotal roles of 
miRNAs during the establishment, maintenance, regulation and termination of primary 
defense responses against invading pathogens (O'Connell et al, 2010; Sonkoly & Pivarcsi, 
2009). Some prominent examples of miRNAs involved in the modulation of innate immunity 
include let-7e, miRNA-9, -34, -146 and -155 among others. These molecules have been 
shown to be involved in processes such as regulation of TLR-expression, NF-κB activation, 
DC differentiation, inflammation and binding ability to pathogens (Androulidaki et al, 2009; 
Bazzoni et al, 2009; Hashimi et al, 2009; Martinez-Nunez et al, 2009; Taganov et al, 2006). 
Hence, miRNAs have become a very powerful tool for studying and understanding how the 
fine tuning of the innate immune system takes place and constitute interesting targets for the 
development of novel therapies against immunological disorders.  
 
Hitherto, no connection of miRNA-133b with the innate immune system has been 
drawn. By stimulating monocytic-like cells with TLR agonists it was shown that the amount 
of miRNA-133b in the cell can be strongly influenced by activation of the cells with 
pathogen associated molecular patterns (PAMPs) (Figure 16). Moreover, in-vitro infection of 
macrophages with non-pathogenic M. bovis BCG, but not pathogenic M. tuberculosis, also 
induced strong miRNA-133b expression during the first 24 hrs. of infection (This finding will 
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be discussed in the next section) (Table 9 and Figure 1). This correlation between activation 
of the innate immune system and miRNA-133b up-regulation strongly implies the latter 
might play an immunoregulatory role during the inflammatory response triggered after TLR 
stimulation. Currently, most of the miRNAs described in the context of inflammation and 
innate immunity have been characterized as negative regulators of molecular signaling 
cascades leading to production of pro-inflammatory cytokines like IL1β, IL6 or TNFα. By 
doing so, miRNA-146a or -147 protect cells from excessive counterproductive innate 
immune responses because their own expression is up-regulated after activation of the 
inflammatory response (Liu et al, 2009a; Taganov et al, 2006). Contrary to this, the data 
presented here showed miRNA-133b as a small molecule with the ability to positively 
regulate and enhance the NF-κB signaling triggered by TNFα or poly(I:C). As a consequence 
of this, four and seven times more IL6 or 8 were synthesized, respectively (Figure 18B). 
Thus, miRNA-133b represents a novel class of immunorelevant miRNA whose role is not to 
block the activation process triggered after pathogen recognition, but rather to boost it.  
 
As demonstrated by the NF-κB luciferase assays, miRNA-146a is able to block the 
hyper activation observed as a consequence of increasing the intracellular levels of miRNA-
133b (Figure 19). This raises the question about the interaction between co-expressed 
miRNAs and the biological consequences of this. One possibility, as shown here, is that co-
existing molecules antagonize each other as a mechanism to avoid a dangerous polarization 
of the cellular response. In this case, the final outcome of the response would strongly depend 
on the kinetics of induction of the miRNAs and their target molecules. Furthermore, 
biochemical and biophysical properties such as stability and half-life of the molecules would 
also benefit the one or other direction of the cellular response. Thus, the biological effect of 
miRNA-133b and its pro-inflammatory activity might not only depend on whether it is 
expressed or not, but also on the co-existence of other miRNAs. 
 
Herein it was shown that the NF-κB hyperactivity was specific for miRNA-133b 
transfectants (Figure 18A). Based on this, it is tempting to postulate a negative regulator of 
NF-κB as one of the genes targeted by miRNA-133b. Indeed, many interesting NF-κB 
regulators such as tumor necrosis factor inducible protein A20 (A20) or protein phosphatase 
2 catalytic subunit alpha isoform (PP2A) show a good complementarity to miRNA-133b and 
are predicted as potential targets in-silico (Barisic et al, 2008; Song et al, 1996). In order to 
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test this possibility, 3´-UTR luciferase reporter constructs were generated and the mRNA 
expression and protein levels of several of these candidate genes was analyzed after 
transfection of HeLa cells with miRNA-133b (data not shown). Unfortunately, despite 
several attempts none of the predicted targets showed a miRNA-133b-dependent expression 
pattern. Hence, the identity of the negative regulator of NF-κB being down-regulated after 
miRNA-133b treatment has remained elusive. Its identification will be of crucial importance 
for the understanding of phenotype caused by miRNA-133b.  
 
Further hints of a potential involvement and importance of miRNA-133b as a 
regulator of innate immune mechanisms are provided by the molecules whose expression is 
impaired by it. As mentioned previously, OPG has a high affinity for RANKL and this 
interaction is of crucial importance for bone homeostasis. Besides its pivotal role as central 
regulator of osteoclast development and function, RANKL is also of extreme importance in 
various processes associated to innate immunity. It augments the ability of DCs to stimulate 
naive T-cell proliferation, regulates the production of pro-inflammatory cytokines and 
potentiates the antigen presentation capacity of macrophages (Anderson et al, 1997; 
Maruyama et al, 2006; Park et al, 2005). Similarly, TRAIL, the other OPG ligand, also 
executes central functions associated with the innate immune system. For instance, TRAIL is 
up-regulated on monocytes and macrophages after stimulation with LPS or IFNβ (Ehrlich et 
al, 2003; Halaas et al, 2000). Furthermore, IFNγ stimulation induces TRAIL on the surface of 
monocytes, DCs and natural killer (NK) cells (Fanger et al, 1999; Griffith et al, 1999). 
Importantly, membrane bound TRAIL displayed by NK cells constitutes one of the main 
killing mechanism used by these cells to combat tumors (Smyth et al, 2001). Future work 
should explore the importance of miRNA-133b in the aforementioned processes. An 
important task here will be to determine the expression levels of miRNA-133b among the 
different cell types and under distinct activation stages of the immune system.  
 
 
4.4 miRNA-profile of mycobacterial infection 
 Despite tremendous accumulating evidence of the importance of miRNAs for the 
appropriate function of the immune system, currently no data are available on the role they 
could play during mycobacterial infections. By performing miRNA-expression analysis of 
macrophages infected either with pathogenic M. tuberculosis H37Rv or apathogenic M. bovis 
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BCG, several miRNAs displaying an altered expression profile after 24 and 48 hrs. infection 
were identified (Table 9 and Figure 1). The list of miRNAs differentially expressed included 
molecules that have been previously well characterized in the context of innate immunity e.g. 
miRNA-146a, -155 and let-7e (Androulidaki et al, 2009; Martinez-Nunez et al, 2009; 
O'Connell et al, 2007; Taganov et al, 2006). Notably, also species with no previous record of 
immunoregulatory activity could be detected. Most differentially regulated miRNAs showed 
subtle expression changes compared to uninfected cells. Rather than being an intrinsic 
characteristic of the experimental system used here, this has become a general observation of 
different groups performing miRNA profiling experiments. The current consensual model in 
the miRNA field is that even marginal expression level changes may lead to severe effects 
and phenotypes (Baek et al, 2008; Linsen et al, 2008; Selbach et al, 2008). The reason for this 
has been attributed to the pleiotropic nature of miRNA regulatory function which allows 
these short RNAs to interfere, or promote, simultaneously different molecular mechanisms 
and signaling pathways. Hence, even small changes like those observed for most miRNAs 
detected with our setup of mycobacterial infection might be relevant.  
 
 Currently, the study of miRNA function and relevance during M. tuberculosis 
infection is particularly hindered by the difficulty to perform transfection and over-expression 
studies in biologically relevant host cells i.e. macrophages and DCs (Lee et al, 2009b; Zhang 
et al, 2009). As an alternative to circumvent this technical issue it was decided to first screen 
candidate miRNAs for regulatory properties in the context of TNFα mediated apoptosis and 
signaling using the easily transfectable and well characterized HeLa cell system. TNFα was 
chosen since it plays pivotal roles in the initial and long-term control of TB. For instance, 
gene knockout mice deficient in TNFRI suffer from exacerbated TB (Balcewicz-Sablinska et 
al, 1998; Flynn et al, 1995a; Kaufmann, 2002; Lin et al, 2007). Using this experimental setup 
miRNA-133b was identified as a strong sensitizing agent against TNFα induced cell death 
(Figures 2, 3 and 4). Based on this observation the development of a lentiviral transduction 
platform for over-expressing miRNA-133b in human macrophages was started. 
Unfortunately, generation of these constructs proved to be very challenging, mainly because 
of cloning difficulties related to the complex irregular hairpin structure of miRNA precursors 
that is essential for correct processing and generation of biologically active molecules. Hence 
generation of stable miRNA-133b over-expressing macrophages is still underway. These 
cells will allow the characterization of the involvement of this potent pro-apoptotic molecule 
during the innate immune response to M. tuberculosis.  
Discussion 
79 
 
 As shown by our results, miRNA-133b was strongly induced by macrophages after 24 
hrs. infection with the vaccine strain M. bovis BCG, but not virulent M. tuberculosis H37Rv. 
The importance of macrophage apoptosis for the outcome of mycobacterial infection is still 
unclear because ambivalent experimental evidence has been collected in the past. M. 
tuberculosis could act as pro-apoptotic pathogen that induces cell death in order to escape 
from macrophages and promote extracellular spread of the infection. Indeed, primary human 
alveolar macrophages obtained from bronchoalveolar lavage of TB patients show elevated 
apoptosis levels when compared to healthy control individuals (Klingler et al, 1997; Placido 
et al, 1997).  
 
Moreover, cellular death induction in infected macrophages seems to rely on a novel 
caspase-independent pathway that shares features of both apoptosis and necrosis (Lee et al, 
2006; O'Sullivan et al, 2007). Thus, there is evidence available that supports the concept of 
M. tuberculosis as an apoptosis inducing pathogen. Remarkably, the magnitude of the cell 
death inducing response seems to be strongly dependent on the genetic background of the 
host cell, the bacterial strain and the multiplicity of infection used (Briken & Miller, 2008). In 
contrast to this, prevention of host apoptosis could represent a strategic tool of virulent 
mycobacteria to evade a key-step of innate immunity and perpetuate their replication niche. 
Several lines of robust evidence support the blockade of host cell apoptosis as an important 
virulence mechanism of M. tuberculosis. For instance, it is known that pathogenic 
mycobacteria can induce anti-apoptotic genes much stronger than non-virulent high apoptosis 
inducing strains (Dhiman et al, 2007; Sly et al, 2003; Spira et al, 2003). Furthermore, M. 
tuberculosis inhibits the extrinsic apoptotic pathway by modifying the expression of death 
receptors such as Fas and soluble TNF receptor 2 (sTNFR2) (Balcewicz-Sablinska et al, 
1998; Oddo et al, 1998).  
 
Finally, the strongest evidence for the anti-apoptotic nature of M. tuberculosis was 
provided by the identification of three genes (nuoG, soda and PknE) in its genome that 
encode proteins responsible for reduced levels of infection-triggered apoptosis (Hinchey et al, 
2007; Jayakumar et al, 2008; Velmurugan et al, 2007). In summary, several lines of 
conclusive evidence support the ability of mycobacteria to actively manipulate the apoptotic 
response of its host. This seems to occur according to the necessity of intracellular 
mycobacteria to either replicate safely within the macrophage or, abandon it and disseminate. 
Given their pivotal role for the regulation of the apoptotic program, miRNAs, including 
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miRNA-133b, could be used for a better dissection of the molecular mechanisms that allow 
mycobacteria to control the fate of the host cell. Moreover, active manipulation of the 
miRNA repertoire of the target cell by the invading pathogen could represent a previously 
unforeseen mechanism of host manipulation. In fact, this has already been described for the 
bacterial plant pathogen Pseudomonas syringae. This pathogen has developed the ability to 
inject effector proteins into the host cell that allow it to manipulate the host miRNA 
machinery (Navarro et al, 2008). In order to approach this question, the development of 
suitable miRNA over-expression and repression tools for use in human macrophages and 
DCs is imperative.  
 
 Besides the potential of miRNAs as tools for deciphering and approaching host-
pathogen interactions, they could also provide valuable information about the immune status 
of the host cell and even the whole organism. From this perspective it is feasible to envision 
miRNA signatures of TB patients as a possible way of characterizing the disease state. 
Moreover, such expression profiles could have both diagnostic and prognostic value. Indeed, 
first studies have already determined that miRNAs can be even more accurate than traditional 
expression profiles when classifying tumors according to their developmental lineage (Lu et 
al, 2005). Even more, the level of certain miRNAs can help predict the effectiveness of 
pharmacological treatment. This has been demonstrated in human biopsies of hepatitis C 
patients, where the expression levels of miRNA-122 negatively correlate with the success of 
IFN therapy (Sarasin-Filipowicz et al, 2009). Hence, performing miRNA profiling in the 
context of infectious diseases, especially TB, could open a new window for a deeper 
understanding of pathogenic mechanisms. Furthermore, such signatures represent a 
promising platform for the development of new diagnostic and prognostic tools.  
 
 
4.5 miRNA-133b: one miRNA, many targets 
 Currently, an important question in the miRNA field is whether these small regulatory 
molecules achieve their physiological impact through repression of a single or a few cardinal 
targets, or via the cumulative impact of impairing the expression of large sets (sometimes 
hundreds) of targets (Wallach & Kovalenko, 2009). Whereas most experimental evidence 
supports the latter option, there are some reported cases where siRNA-mediated down-
regulation of one single gene resembled miRNA-mediated phenotypes. For instance, in mice, 
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specific knockdown of SHIP1 in the hematopoietic system following retroviral delivery of a 
miRNA-155-formatted siRNA against SHIP1 resulted in a myeloproliferative disorder, with 
striking similarities to that observed in miRNA-155-over-expressing mice (O'Connell et al, 
2009). According to the data presented here, four critical anti-apoptotic genes could be 
identified, whose expression is impaired simultaneously (directly or indirectly) by miRNA-
133b. Importantly, as determined by gene-specific knockdown experiments using siRNAs, 
none of these genes was capable by itself of phenocopying the pro-apoptotic effect of 
miRNA-133b in its whole magnitude (data not shown). This supports the idea that the effect 
mediated by miRNA-133b is the consequence of multiple synergistic small changes in the 
expression levels of various genes, rather than being attributable to the impaired expression 
of one single master gene. Nevertheless, it is impossible to exclude that the latter might be the 
case and, that the identity of the most important miRNA-133b target is still missing. Further 
studies are necessary in order to increase the list of genes being regulated by miRNA-133b. 
 
 
4.6 Technical aspects: The challenge of miRNA-target identification 
 Regardless of the enormous advancement achieved in the field of miRNA research 
during the last decade, identification of targets genes is still considered a gigantic technical 
challenge. This represents a major threat for the expansion of our understanding of miRNA 
function since the latter is ultimately defined by the genes a given miRNA targets and the 
effects it has on their expression (Mendes et al, 2009). Currently, most miRNA target fishing 
experiments use in-silico sequence analysis and prediction as a starting point. Though 
helpful, this kind of bioinformatic approach is still prone to high rates of false positive 
predicted targets. Furthermore, the fact that miRNAs might exert their function either by 
provoking mRNA cleavage or translation arrest constitutes a further hurdle for efficient target 
gene identification. Herein results are presented that were obtained after using a mixed 
miRNA target identification strategy. This consisted of using state-of-the-art methods to 
assess the impact of miRNA-133b both on the transcriptome and proteome of transfected 
cells. As a big advantage, the characterization of miRNA-133b as a pro-apoptotic molecule 
allowed us to narrow the target search to anti-apoptotic and tumor-suppressing molecules. 
This system proved to be successful as demonstrated by the discovery of FAIM, OPG, 
GSTP1 and FASN as genes whose expression is impaired by miRNA-133b. Unfortunately, 
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the complexity of this approach as well as the high costs associated to it excludes its 
application as a routine strategy. 
 
Two more aspects complicate the identification of miRNA targets. First, as discussed 
previously, miRNA over-expression often leads to rather minute changes of mRNA and 
protein levels of targeted genes (Baek et al, 2008; Selbach et al, 2008). This raises the 
question as to what extent small changes in protein levels can be considered biologically 
relevant. By following the traditional approach of focusing on genes showing the most drastic 
effects researchers might overlook those that are really important since they take over central 
roles. MiRNAs exemplify that regulation of biological systems is not a question of strength at 
the single gene level, but rather of cumulative and synergistic subtle variations of the protein 
repertoire. Second, as demonstrated by OPG and FASN, finding the exact region being 
targeted by the miRNA of interest is still not an easy task. It has been recently shown that 
regions other than the 3´-UTR of a gene can also function as miRNA docking sites (Zhou et 
al, 2009). Since most of the currently online available in-vitro prediction tools do not analyze 
the entire mRNA sequence, they offer only limited prediction power. Hence, they might not 
detect and predict numerous non-canonical miRNA binding sites (Lee et al, 2009a; Tay et al, 
2008). Moreover, current targeting validation systems are designed to identify binding to the 
3´-UTR but not other regions of a gene. Thus, as our knowledge of the mechanisms 
underlying miRNA function expands, the challenge of designing and establishing more 
accurate target validation systems is growing.  
 
 Last but not least, even if a gene shows an expression pattern that can be specifically 
influenced by a miRNA (like FASN or OPG in this study), this does not necessarily mean 
that a direct interaction between the small RNA and mRNA is taking place. Current miRNA 
target identification techniques do not discern between direct targeting and downstream 
effects. Hence, in some cases gene regulation might be a consequence of impaired activity of 
a central gene expression regulator e.g. transcription factors. This might be less important for 
the phenotypic description of miRNA effects, but must be considered when elucidating the 
exact molecular mechanisms responsible for a given cellular phenotype. 
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5. Conclusions & Outlook 
The work presented here dealt with the characterization of miRNA-133b, a molecule 
first detected during a screen aimed at the identification of miRNAs differentially regulated 
during mycobacterial infection of human macrophages. Using an ex-vivo model of DR-
mediated apoptosis it was shown that miRNA-133b has very strong pro-apoptotic properties. 
Treatment of HeLa cells with this molecule resulted in strong sensitization towards TNFα or 
FasL-triggered apoptosis and exacerbated TRAIL sensitivity. Hitherto, this work represents 
the first description of a miRNA harboring the ability to manipulate the signal pathway 
composed of DRs and their ligands. As shown by our results, four different mechanisms 
could be identified by which miRNA-133b renders cells more prone to undergo apoptosis 
(Scheme 14).  
 
 
Scheme 14. miRNA-133b as regulator of apoptosis and the inflammatory response mediated by NF-kB 
 
First, it down-regulates the abundance of FAIM and OPG, two anti-apoptotic proteins 
involved in the regulation of DR-induced cell death in many different biological settings. 
Secondly, miRNA-133b down-regulates the expression of the oncogenes GSTP1 and FASN. 
By doing so it impairs the ability of tumor cells to cope with chemical stress and self-supply 
with important molecules, respectively. Both GSTP1 and FASN have been well characterized 
in the context of tumorigenesis and immune evasion and represent important therapeutic 
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targets. Importantly, miRNA-133b represents the first described post-transcriptional 
expression regulator for all four genes. Hence, our results contribute to a better understanding 
of the mechanisms governing the expression of central oncogenes. Future work should focus 
on the characterization of miRNA-133b in different cancer models and its potential as novel 
target for therapeutic treatment. Given the consistent down-regulation of miRNA-133b in 
human tumors of different etiology, it would also be interesting to explore its potential 
application as diagnostic and prognostic marker. 
 
 The molecules identified in this work as miRNA-133b targets accomplish important 
tasks in a variety of biological systems. Furthermore, most of them have been well 
characterized in the context of disease and represent important therapeutic targets. Given the 
current knowledge that supports a wider expression pattern of miRNA-133b future work 
should explore its role during the regulation of processes such as neuronal development, 
osteogenesis, cardiac and skeletal muscle development, B-cell development or lipogenesis. 
Further attempts should also aim at expanding and enriching the list of genes targeted by 
miRNA-133b. This will allow unveiling its biological relevance and regulatory potential.  
 
Herein first evidence was provided for a role of miRNA-133b in the context of innate 
immunity. Our results link miRNA-133b expression to TLR-mediated pathogen recognition. 
Notably, contrary to most miRNAs associated so far with innate immunity, miRNA-133b 
seems to facilitate pro-inflammatory processes rather than to impair them. As demonstrated 
by our results, miRNA-133b transfection of cells leads to enhanced NF-κB activity and 
increased synthesis of pro-inflammatory cytokines such as IL6 and 8. Given the central role 
of NF-κB among transcription factors and its extreme importance for proper biological 
function, follow-up experiments should definitely aim at elucidating the mechanisms 
responsible for miRNA-133b mediated enhanced NF-κB activity. In the same line, generation 
of miRNA-133b and αmiRNA-133b over-expressing macrophages will allow further 
characterization of the relevance of miRNA-133b in the context of primary immune response 
to mycobacterial infection.  
 
 The miRNA profile presented here is a simplified first attempt to characterize the role 
of these small regulators during mycobacterial infection. It proves that bacterial challenge 
modulates miRNA expression levels. Based on this first line of evidence, the possibility of 
Conclusions & Outlook 
85 
 
generating miRNA expression profiles of TB patients should be considered. Currently, the 
access to more modern sequencing and profiling techniques would allow a deeper and, 
probably, more sensitive quantification of changes in miRNA levels. This information is very 
valuable since it could provide new mechanistic insights and, it could have diagnostic and 
prognostic significance.  
 
 Finally, this work constitutes the first characterization of miRNA-133b in the context 
of DR-mediated apoptosis and innate immunity regulation. Our results show miRNA-133b as 
a very versatile and potent controller of cellular fate. The evidence provided here, together 
with the current knowledge about miRNA-133b expression in different cancer types and its 
role as regulator of the intrinsic apoptotic pathway, indicate that miRNA-133b plays 
important roles during processes such as cellular transformation and tumor development. 
Hence, miRNA-133b could represent an interesting molecular target for therapeutic 
treatment. Follow-up studies should focus on the characterization in other relevant biological 
models of the molecular mechanisms described here.  
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7. Appendix 
7.1 Published cancer miRNA expression profiles showing miRNA-133 down-regulation 
Table 11. List of published reports showing an impaired expression of miRNA-133b in tumor cells and/or 
clinical samples 
Cancer type Description Reference 
 
Multiple cancer types 
 
 
miRNA-133b specific down-regulation 
in human biopsies from 8 different 
tumor types compared to matched 
healthy tissue 
 
 
(Navon et al, 2009) 
 
 
Human non-small cell 
lung cancer (NSCLC) 
 
 
miRNA-133b expression is strongly 
impaired in lung tumor compared to 
uninvolved tissue 
 
 
(Crawford et al, 2009) 
 
 
Head and neck/oral 
cancer (HNOC) 
 
 
Several studies demonstrating a lower 
expression of miRNA-133b in HNOC 
 
 
(Kozaki et al, 2008; Liu et al, 
2009b; Tran et al, 2007; Wong 
et al, 2008a; Wong et al, 
2008b) 
 
 
Bladder cancer 
 
 
Impaired expression of miRNA-133b in 
bladder cancer biopsies compared to 
healthy control tissue 
 
 
(Ichimi et al, 2009) 
 
 
Colorectal cancer 
 
 
Real-Time PCR examination of 
colorectal cancer samples and non-
neoplastic tissue from patients revealed 
a diminished miRNA-133b expression 
 
 
(Bandres et al, 2006) 
 
 
Human germ cell 
tumor 
 
 
Decreased expression of miRNA-133b 
in testicular germ cell tumors compared 
to control tissue 
 
 
(Gillis et al, 2007) 
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